

# APBMT Annual Report 2021

**Asia-Pacific Blood and Marrow Transplantation Group**  
**SECRETARIAT OFFICE / DATA CENTER OF APBMT**



Copyright APBMT Annual Report 2022

Worldwide Confidentiality Note: Dissemination, distribution or copying of this document or the information herein by anyone other than the approved recipient is prohibited. If you are not the intended recipient, please inform APBMT Secretariat ([office@apbmt.org](mailto:office@apbmt.org)).

Prior approval must be sought from APBMT before releasing any data from this document publicly, and APBMT must be acknowledged as the data source. The suggested citation is : "APBMT Annual Report 2022".

This document contains information on hematopoietic stem cell transplants and cellular therapies provided voluntarily by participating countries/regions in the Asia-Pacific region. The data and its analysis are the property of APBMT. This APBMT resource is intended for use by its members and approved participating clinical and research organizations.

While all care has been taken in the compilation of this document, no responsibility can be taken for misuse of the data or for data errors that have been unintentionally included.



**Asia-Pacific Blood and Marrow  
Transplantation Group  
(APBMT)  
Annual Report  
2021**

**Secretariat Office / Data Center of APBMT**

**E-mail: [office@apbmt.org](mailto:office@apbmt.org)  
Website: <https://www.apbmt.org>**

# Contents

## **Introduction**

- General Overview 2021
- Bylaws
- Organizational Tree
- Principal Member List

## **Annual Congresses**

- Guidelines for the hosting of the APBMT annual congress
- Previous and Future Congresses
- The Number of Attendees for Each Annual Congress from 2012 to 2021

## **Registry Committee**

- About Registry Committee
- About Activity Survey
- About Outcome Registry
- Registry Committee Member List

## **Nuclear Accident Management (NAM) Committee**

- NAM Committee Activities and Member List

## **Executive Board**

- Executive Board Activities
- Executive Board Members

## **Collaboration with Other International Registries**

- General Information
- History of International Scientific Symposia

## **Blood Cell Therapy -The Official Journal of APBMT-**

- About the Journal
- Editorial Board Member List
- List of the Accepted Articles

## **Appendix**

- Cooperate Members and Banner Contributions

# Introduction

## General Overview 2021

All 22 of APBMT's participating countries/regions are listed here. (As of December 2021)

Australia  
Bangladesh  
Cambodia  
China  
Hong Kong  
India  
Indonesia  
Iran  
Japan  
Korea  
Malaysia  
Mongolia  
Myanmar  
Nepal  
New Zealand  
Pakistan  
Philippines  
Singapore  
Sri Lanka  
Taiwan  
Thailand  
Vietnam



This Annual Report is the 14th edition overall and the second edition following our transition to this new digital format. It includes APBMT activities from January to December in 2021. Though the COVID-19 pandemic continued to powerfully influence the field of HSCT medicine in this region throughout the year, all doctors and allied health professionals made a great effort to care for patients with hematological diseases.

The 26<sup>th</sup> annual congress in Thailand was held on the hybrid platform and the organizing committee in Thailand successfully convened it in collaboration with the APBMT Executive Board. APBMT approved new guidelines for the hosting of the annual congress this year, and future annual meetings will be run in accordance with these guidelines.

Please note that, the results of the Activity Survey are separated from the Annual Report from the last edition. You can find them on the APBMT website:

<https://www.apbmt.org/research/registry/survey>

# **BYLAWS OF THE ASIA PACIFIC BLOOD AND MARROW TRANSPLANTATION GROUP (APBMT)**

## **ARTICLE 1**

### **Name of the Group**

The Asia Pacific Blood and Marrow Transplantation Group, hereafter referred to as APBMT was established in 1990 to allow doctors, other health professionals and scientists in the Asia Pacific region involved in clinical blood and marrow transplantation and therapies related to hematopoietic stem cell transplantation to collaborate and promote high quality blood and marrow transplantation in the region.

## **ARTICLE 2**

### **Incorporation**

APBMT is incorporated as Corporate Juridical Person for scientific and educational purposes under the laws of Japan.

## **ARTICLE 3**

### **Purpose of APBMT**


The group aims to promote all aspects associated with the hematopoietic stem cell transplantation (HSCT) and related therapies in the Asia Pacific region, which includes:

- To ascertain and provide the updated status of haematopoietic stem cell transplantation (HSCT) in the Asia Pacific region.
- To steer and regulate the HSCT Registry in the Asia Pacific region (Asia Pacific Blood and Marrow Transplantation Group Registry: APBMT Registry)
- To share current knowledge of all aspects of HSCT to promote and maintain the highest standards of care, and to work towards a set of standards and accreditation of transplant units.
- To provide training opportunities in HSCT in the Asia Pacific region.
- To promote collaborative research in the Asia Pacific region.
- To collaborate with other international organizations related with HSCT
- To work as a core voting member of WBMT

## ARTICLE 4

### Organization

The schema of the organization in APBMT indicates below.



**4. Membership** Any persons involved in the treatment of recipients and donors (such as physicians, nurses, laboratory technicians, persons related to stem cell donor programs or pharmaceutical companies), who are involved in HSCT and agree with the purpose of the group can become a member (see above section). New members are admitted by submitting a membership application form and CV up to 2 pages to the Secretary Office. This application must include the signature of an APBMT member as a presenter. There are two different kinds of memberships; Scientific members (physicians, nurses, laboratory technicians, persons related to stem cell donor programs) and Corporate members (pharmaceutical and for-profit companies). Scientific members include Regular, Associate, Affiliate, Honorary and Emeritus members. All members have to pay annual membership fees except for the Honorary and Emeritus members.

#### 4.1 Regular members

Regular members consist of members from medical fields with an M.D. or Ph.D sufficient experiences and demonstrated in hematopoietic stem cell transplantation / cellular therapy. A proposed new member must provide a membership application form and CV that includes professional qualification, work experiences, current employment and place of work to the Secretariat Office. Regular members must agree to abide by the regulations of APBMT, to participate in scientific endeavors of APBMT, to have good ethical and moral standards as well as no criminal record, as expected by professional societies. Regular members can attend the Business meeting but do not have voting right. Regular members can elect and can be elected as Scientific Committee members within each country.

#### **4.2 Associate members**

Individuals with and M.D. or Ph.D who do not meet the criteria for regular membership will become Associate members. Associate members cannot attend the Business meeting and do not have voting right. Applicants are required to submit a membership application form and CV to the Secretariat Office.

#### **4.3 Affiliate members**

Professionals who are members of HSCT / cellular therapy team or interested in HSCT / cellular therapy (NP, PA, Pharm D, RN etc.) are eligible to be Affiliate members. Affiliate members cannot attend the Business meeting and do not have voting right. Applicants are required to submit a membership application form and CV to the Secretariat Office.

#### **4.4 Emeritus members**

Anyone in APBMT who has contributed in a significant way to its development is eligible to become Emeritus Members. Emeritus members are nominated by the Executive Board and are approved by the Scientific Committee at the business meeting. Emeritus Members are eligible to participate in the business meeting.

#### **4.5 Honorary members**

Individuals who are not an APBMT member but have contributed to the establishment or the development of APBMT are eligible to become an Honorary member. Honorary members are nominated by the APBMT members and are approved by the Scientific Committee at the business meeting. Honorary

members are ineligible to participate in the Business meeting.

#### **4.6 Corporate members**

Representatives of commercial and for-profit companies can become Corporate members. Corporate members cannot attend the Business meeting and do not have voting right. Applicants are required to submit a membership application form and CV to the Secretariat Office.

#### **4.7 Scientific Committee**

Scientific Committee is the supreme decision-making body in APBMT. Each country can elect and nominate 1 voting member as the country representative. The vote is casted by the country representative but this right may be transferred to a designated substitute. If there is more than one nominee from one country, the Scientific Committee can vote to select one candidate. The names of the current members of scientific committee are listed and updated annually. The Chairman of the Executive Board, who also serves as the Chairman of the Scientific Committee, has the deciding vote if the vote is otherwise tied.

New Scientific Committee members need to be recommended by the current members of Scientific Committee among the members of the Regular Members and to get approval in the business meeting. Decisions are taken by majority voting (One vote/one country). A proposed new member must provide a brief CV up to 3 pages. The criteria to be a Scientific Committee Member include proven medical and/or scientific experience in HSCT; willingness to committee and participate in scientific endeavors of APBMT; no criminal record, good ethical and moral standards as expected by professional societies.

The Scientific Committee member has the following rights and obligations: 1) To attend the Annual Business Meeting; 2) To elect Executive Board members; 3) To decide on admission of new members; 4) To decide the annual fee for APBMT membership; 5) To make final decision on APBMT policies and its finance.

A Scientific Committee member will lose his/her rights as a representative of his/her country/region when he/she leaves his/her original country/region permanently.

#### **4.8 Executive Board**

The Executive Board of APBMT steers the group for administration and all decisions that need to be taken for functioning of the organization in accordance

with the constitution and bylaws of the organization. The Executive Board is responsible for all running operations and decisions that are not due to be taken by the Scientific Committee at the annual meeting. The Executive Board, appointed by the Scientific Committee, will act on behalf of all members for regular decisions during the period between Scientific Committee meetings. During this period, the Scientific Committee need not be consulted unless a decision would affect the bylaws or contravene a decision previously made by the Scientific Committee. The Executive Board consisted of regular members (only one member permitted from one country) elected from the Scientific Committee. The maximum number of members of the Executive Board is nine. The Chairman of Executive Board represents APBMT.

#### **4.9 Officers of the Executive Board**

1. Scientific Committee elects a) one Chairman of Executive Board, b) one Vice Chairman of Executive Board, c) several other Members of Executive Board including one Secretariat / Treasurer. The members of the Executive Board are elected by the business meeting, and serves for two years and may be re-elected for another term of two years.
2. The function of the Chairman of Executive Board is to promote and coordinate all activities of APBMT. These include fund raising, coordination of Working Group activities, giving suggestions to the organizers of the annual meeting, and negotiations with other organizations on behalf of APBMT.
3. The Vice Chairman supports the Chairman and will perform the duties of the Chairman in the absence.

#### **4.10 Secretariat/Treasurer**

Secretariat / Treasurer shall oversee the maintenance of a permanent record of APBMT. The Secretariat / Treasurer shall have oversight of the budget of APBMT. The Secretariat / Treasurer Office works for the development and the maintenance of the group under the collaboration with the Chairman of Executive Board, the Chairman of the next annual congress, and the members of Executive Board and Scientific Committee.

### **ARTICLE 5**

#### **Committees and Working Groups**

##### **5.1 Committees**

APBMT will have the following Standing Committees to help with its work.

1. Membership Committee
2. Registry Committee
3. Program Committee
4. Nuclear Accident Management (NAM) Committee
5. Editorial Board of the Blood Cell Therapy, the Official Journal of APBMT

Each of these committees will have a specific term of reference.

## **5.2 Working Groups**

The aim of Working Groups is to enhance research in focused areas. The Executive Board and Scientific Committee of APBMT determine the formation of Working Groups as required. The application of the new Working Group and its chair person is approved by the members of the Scientific Committee in the Business Meeting (see Annex). The chair person of each Working Group is elected for three years and may stand for reelection once. The substructure of the Working Group is defined by the chair person in consultation with the Executive Board. Regular Members are encouraged to participate in one or more Working Groups according to their particular interests. The Working Group chair person must submit annual activity reports to the Scientific Committee and the Executive Board. The chairperson should adhere to the Working Group responsibilities, which are specified separately from the bylaws.

## **ARTICLE 6**

### **Meetings**

#### **6.1 Annual Congress**

Any countries participating in APBMT can propose to be a host country of the Annual Congress. Host country of the future Annual Congresses will be decided by the Scientific Committee. The President of the next annual congress cooperates with the Executive Board for the year preceding the annual congress. The format of the meeting is to be standardized (see Annex section below).

#### **6.2. Business Meeting**

The Scientific Committee will open the Business Meeting at least once a year. One of them will be held during the annual meeting. It is co-chaired by the Chairman of the Executive Board and the President of the Annual Congress. The Board may establish subcommittee / working party as the need arises.

### **6.3 Board Meeting**

The Executive Board of the APBMT shall meet in person at the annual meeting. It is presumed that all members will attend this meeting unless there are unavoidable personal circumstances. In addition, the board will meet via conference calls every 4-8 weeks, as needed. All members are expected to attend all scheduled board meetings.

## **ARTICLE 7**

### **7.1 APBMT Registry**

A major activity of the APBMT will be to guide the development of national registries in each country. This data will then be collected into the combined APBMT registry in formats compatible with other international registries. Both activities and outcome data will be collected every year.

### **7.2 Annual Report**

The list of registrants and summary of analyses are published in the APBMT Annual Report of each year, which is distributed to the APBMT member and related persons / organizations. The results published in the APBMT Annual Report is confidential, however, it can be quoted after written approval from APBMT and accompanied by proper acknowledgement.

### **7.3 Rules on the use of the Registry data**

Data are restricted to publication in a scientific article and / or presentation at academic meetings. APBMT contributions must be appropriately acknowledged in all presentations and publications prior to the release of the data and analyses. Written Applications for these purposes are limited to Scientific Committee Members, Working Groups and the Data Center of APBMT for the time being. Written requests from other academic organizations or commercial companies will be assessed and if approved a cost recovery will be charged depending on the amount of work. Confidentiality of source information will be protected in accordance with the laws of individual centres and countries. An application form is attached as a separate sheet. The Registry Committee will evaluate all applications and approval made after consultation with the Executive Board.

## **ARTICLE 8**

## **Finance**

### **8.1 Membership Fees:**

All the Regular Members are required to pay annual membership fees on an individual basis (see Annex). The members who paid the membership fees can receive up-to-date information including the survey data from APBMT office and also may have the advantage of discount of the registration fees at annual congress.

### **8.2 Statement of accounts of annual APBMT congress**

An audited statement of accounts must be prepared by the organizing committee for each annual APBMT meeting within one year of its completion and submitted to the APBMT Headquarters and presented at the annual business meeting.

## **ARTICLE 9**

### **Amendments**

9.1 These Bylaws may be amended at any annual business meeting of the Scientific Committee Amendments to the Bylaws may be proposed in writing to the Executive Board and must be submitted at least ninety days prior to the annual meeting. In addition, the Executive Board may initiate proposed amendments to the Bylaws.

The proposed amendments, together with the Executive Board's recommendation, shall be distributed to members of the Scientific Committee at least thirty days before the annual meeting at which it is to be considered. To be adopted, an amendment must be approved by at least two thirds of voting at the annual meeting.

9.2 Annexures may be amended by the Executive Board, (with a minimum of two third majorities of the members of the Executive Board) and report to the Scientific Committee.

### **Annexures:**

1. Committees - Terms of Reference to be determined.
2. Working Groups - Terms of Reference to be determined.
3. Annual Congress – Format of the meeting to be formulated
4. The APBMT Registry
5. Financial Issues

6. The Scientific Committee members: In addition to the criteria to be a Scientific Committee Member described in APBMT Bylaw (4.7 Scientific Committee), the candidate must have served as a regular member for the past three years with the consecutive payment of annual membership fee. No term limits are set for Scientific Committee Members. However, the members are required to participate in at least 2 out of 4 most recent APBMT Annual Congress, and consecutively pay annual membership fee in order to maintain their membership. In addition, their willingness of serving as Scientific Committee Members is to confirm every two years. No limits are set for the maximum number of Scientific Committee members in each country/region participating APBMT

7. Others

(Detailed rules such as payments and duties for the members are described in the annexure)

Establishment: October 1, 2009

History of revision:


December 31, 2010

October 31, 2015

November 1, 2016 (Annexure 6 was added.)

August 31, 2019

# Organizational Tree of APBMT



# Principal Member List

## *Executive Board members*

Shinichiro Okamoto (Chairman, Japan)      Alok Srivastava (Vice-chair, India)      David D Ma (Australia/New Zealand)  
He Huang (China)      Amir Ali Hamidieh (Iran)      Jong Wook Lee (Korea)  
William YK Hwang (Singapore)

## *Scientific Committee Members ( \*Executive Board members )*

Yoshiki Akatsuka (Japan)      Otgonbat Altangerel (Mongolia)      Shashikant Apte (India)  
Khishigjargal Batsukh (Mongolia)      Carmella Bingcang (Philippines)      Pheng Bora (Cambodia)  
Udomsak Bunworasate (Thailand)      Po-Min Chen (Taiwan)      Tzeon-Jye Chiou (Taiwan)  
Sharat Damodar (India)      Gin Gin Gan (Malaysia)      Lallindra Gooneratne (Sri Lanka)  
Aye Aye Gyi (Myanmar)      Amir Ali Hamidieh (Iran) \*      Suradej Hongeng (Thailand)  
He Huang (China) \*      Xiao-Jun Huang (China)      Tai-ju Hwang (Korea)  
William YK Hwang (Singapore) \*      Hyoung Jin Kang (Korea)      Mohiuddin Khan (Bangladesh)  
Navin Khattry (India)      Bor-Sheng Ko (Taiwan)      Mickey Koh (Singapore)  
Hoon Kook (Korea)      Hsiao Liang-Tsai (Taiwan)      Jong Wook Lee (Korea) \*  
Albert Lie (Hong Kong)      Kai-Hsin Lin (Taiwan)      Kai-yan Liu (China)  
David D Ma (Australia/New Zealand) \*      Koichi Miyamura (Japan)      Shinichiro Okamoto (Japan) \*  
Jian Ouyang (China)      Chi Dung Phu (Vietnam)      Bishesh Sharma Poudyal (Nepal)  
Damai Santosa (Indonesia)      Tahir Sultan Shamsi (Pakistan)      Alok Srivastava (India) \*  
Jih-Luh Tang (Taiwan)      Shuichi Taniguchi (Japan)      Takanori Teshima (Japan)  
Artit Ungkanont (Thailand)      Auro Viswabandya (India)      Jianmin Wang (China)  
Jong-Ho Won (Korea)      Tong Wu (China)      Ming Yao (Taiwan)  
Mei Zhang (China)

## *Honorary Members*

Kerry Atkinson (Australia)      John Carter (New Zealand)      Dennis Confer (NMDP)  
John Goldman (EBMT)      Alois Gratwohl (EBMT)      Geoffrey Hill (Australia)  
Mary Horowitz (CIBMTR)      Dietger Niederwieser (EBMT)

## *Emeritus Members*

Suresh H Advani (India)      Shigetaka Asano (Japan)      Lu Xian Cao (China)  
Ardeshir Ghavamzadeh (Iran)      Surapol Issaragrisil (Thailand)      Saengsuree Jootar (Thailand)  
Chun Choo Kim (Korea)      Dong Jip Kim (Korea)      Yoshihisa Kodera (Japan)  
Dao-Pei Lu (China)      Tohru Masaoka (Japan)      Tan Binh Nguyen (Vietnam)  
Philip Rowlings (Australia/New Zealand)      Tapan K Saikia (India)      Pattric Tan (Singapore)

# Annual Congresses

## **Guidelines for the hosting of the APBMT annual congress**

### **Planning and preparation**

- APBMT Annual Congress is organized by APBMT in collaboration with the host country/society each year through an Organizing Committee and a Scientific Program Committee (SPC).
- The chair of the APBMT Board will be a Co-President of the Annual Congress along with a Co-President nominated by the host country.
- Both committees will function as per a schedule drawn up by the APBMT Secretariat for targets to be achieved to the dates of the congress.
- The Organizing Committee will have two Co-chairs - Chair of the APBMT Board/Board nominee with a Co-chair from the host country/society, and the equal number of members nominated by the APBMT Board and the host country/society.
- The Scientific Program Committee (SPC) of Congress will have two co-chairs - one local and one APBMT Executive Board (EB) nominated along with an equal number of local and EB nominated international members.

### **The scientific program will be planned according to the standard format:**

- 1<sup>st</sup> day for APBMT standing committees and working group meetings- Industry symposia / CME program or educational symposia followed by 2 ½ days of the scientific program.
- The program should consist of three major tracks for physicians, nurses, and other specialists (such as laboratory diagnostics, cell and graft manipulation, pharmacists)
- The program should contain both educational sessions and sessions covering recent topics/advances in hematopoietic cell transplantation and related fields.
- Each session has a theme on which there could be 3-4 talks in up to 90min.
- The speakers of each topic should be decided by SPC with the invitation letters to be sent by the Co-Chairs of SPC.
- Try to recruit speakers from APBMT participating countries/regions as much as possible (at least 50%) – giving representation to as many countries from Asian-Pacific (AP) regions AP as possible. Criteria for selection of speakers to be defined and followed.
- No AP country/region should have more than 10% of the total number of speakers from Asian Pacific regions in the entire Scientific Program; however, it is acceptable for a host country to have more speakers depending on their suitability but not exceeding 20% of the total.

- The term “speaker” here is determined as the one listed in the Scientific Program (including Plenary and Educational Session) prepared by the SPC but excluding sponsored symposia.
- The meeting should be organized as a hybrid meeting but with major emphasis on a physical meeting when circumstances permit.

### **Funding**

- APBMT office may directly collect funding support from the international division of a multinational company (MNC), and the local host country will collect the support from domestic divisions of MNCs / local companies.
- The overall cost of hosting the Annual Congress will be shared between APBMT and the host country in the same proportion as the total funds collected from all sources.
- Left over funds after meeting all costs of the Annual Congress will be shared between APBMT and the host country in the same proportion as the overall fund collected.
- The budget for the Annual Congress should therefore be jointly decided between APBMT and the host country through the Organizing Committee and the Co-Presidents.

### **After the congress**

- The hosting country must submit the followings to APBMT Secretariat after the meeting
  - Generate and report the financials
  - Submit a list of all attendees (names, countries and email address if possible)
  - Provide all abstracts for uploading on the Blood Cell Therapy website. The permission should be obtained from presenters when they were submitted
  - Provide photos and PowerPoint presentations made during the Congress for uploading the APBMT website after due permissions from the speakers.

## Previous Congresses

No	Year	City	Presidents
1 <sup>st</sup>	1990	Beijing	Lu Xian Cao
2 <sup>nd</sup>	1991	Nagoya	Tohru Masaoka
3 <sup>rd</sup>	1992	Osaka	Tohru Masaoka
4 <sup>th</sup>	1994	Fukuoka	Tohru Masaoka
5 <sup>th</sup>	1996	Seoul	Dong Jip Kim
6 <sup>th</sup>	1998	Taipei	Yao-Chang Chen
7 <sup>th</sup>	2000	Bangkok	Surapol Issaragrisil
8 <sup>th</sup>	2002	Mumbai	Suresh Advani
9 <sup>th</sup>	2004	Tehran	Ardeshir Ghavamzadeh
10 <sup>th</sup>	2005	Hangzhou	Dao-Pei Lu
11 <sup>th</sup>	2006	Nagoya	Yoshihisa Kodera
12 <sup>th</sup>	2007	Beijing	Dao-Pei Lu
13 <sup>th</sup>	2008	Taipei	Po-Min Chen
14 <sup>th</sup>	2009	Seoul	Chun-Choo Kim
15 <sup>th</sup>	2010	Phuket	Saengsuree Jootar
16 <sup>th</sup>	2011	Sydney	David Ma / Philip Rowlings
17 <sup>th</sup>	2012	Hyderabad	Tapan K Saikia / Alok Srivastava
18 <sup>th</sup>	2013	Ho Chi Minh City	Tan Binh Nguyen
19 <sup>th</sup>	2014	Hangzhou	He Huang / Xiaojun Huang
20 <sup>th</sup>	2015	Okinawa	Shinichiro Okamoto
21 <sup>st</sup>	2016	Singapore	William YK Hwang / Chng Wee Joo / Aloysius Ho
22 <sup>nd</sup>	2017	Tehran	Ardeshir Ghavamzadeh
23 <sup>rd</sup>	2018	Taipei	Ming Yao / Jih-Luh Tang
24 <sup>th</sup>	2019	Busan	Jong Wook Lee / Jong-Ho Won
25 <sup>th</sup>	2020	APBMT/ISBMT (Virtual)	Mammen Chandy
26 <sup>th</sup>	2021	Chang Mai (Hybrid)	Artit Ungkanont

## Future Congresses

- The 27<sup>th</sup> Annual Congress will be hosted by Indian Society for Blood and Marrow Transplantation (ISBMT) in 2022  
October 6 to 9, 2022  
Kochi, India

## The Number of Attendees for Each Annual Congress from 2012 to 2021


2012(INDIA)		2013(VIETNAM)		2014(CHINA)		2015(JAPAN)		2016(SINGAPORE)	
India	118	Vietnam	375	China	646	Japan	159	Singapore	234
China	66	China	82	Japan	31	China	186	China	116
Japan	19	Korea	41	Taiwan	24	Taiwan	51	Japan	62
Korea	15	Japan	32	Korea	16	Korea	41	Korea	44
Vietnam	12	Taiwan	17	United States	11	Singapore	23	Taiwan	28
Australia	11	Thailand	13	India	9	Hong Kong	17	India	25
Germany	8	Hong Kong	7	Singapore	9	Vietnam	16	USA	22
Taiwan	7	Belgium	6	Australia	7	India	11	Thailand	21
Iran	6	Singapore	6	Mongolia	7	Thailand	11	Hong Kong	19
USA	6	France	5	UK	5	Indonesia	9	Malaysia	19
Singapore	4	India	5	Hong Kong	4	USA	7	Bangladesh	15
Philippines	3	Australia	4	Philippines	4	Malaysia	6	Vietnam	15
Bangladesh	2	Iran	4	Vietnam	4	Australia	5	Australia	13
Belgium	2	United States	4	France	3	Philippines	5	Iran	11
France	2	Germany	3	Iran	3	UK	4	Philippines	10
Hong Kong	2	Mongolia	3	Thailand	3	Germany	2	Germany	9
Mongolia	2	Spain	3	Germany	2	Iran	2	Sri Lanka	6
Canada	1	Malaysia	2	Myanmar	2	Sri Lanka	2	UK	6
Italy	1	Philippines	2	Pakistan	2	Bangladesh	1	France	4
Myanmar	1	Indonesia	1	Bangladesh	1	Cambodia	1	Mongolia	4
Nepal	1	Ireland	1	Indonesia	1	Canada	1	Indonesia	3
Sweden	1	Myanmar	1	Lebanon	1	France	1	Ireland	3
UK	1	Netherlands	1	Malaysia	1	Italy	1	Italy	3
Missing	3	Sweden	1	South Africa	1	Mongolia	1	Cambodia	2
Total	294	UK	1	Spain	1	Myanmar	1	Myanmar	2
	%	Total	736	Sri Lanka	1	Pakistan	1	Qatar	2
Domestic	40		%	Total	799	Switzerland	1	Belgium	1
Foreign	60	Domestic	61		%	Missing	1	Canada	1
		Foreign	40	Domestic	81	Total	567	Nepal	1
				Foreign	19		%	New Zealand	1
						Domestic	28	Spain	1
						Foreign	72	Switzerland	1
								Total	704
									%
								Domestic	33
								Foreign	67

2017(IRAN)		2018(TAIWAN)		2019(KOREA) *		2020(INDIA) (Virtual)**		2021(THAILAND) (Hybrid)***	
Iran	565	Taiwan	330	Korea	762	India	822	Thailand	525
China	32	China	90	China	125	China	173	Singapore	48
USA	4	Japan	66	Japan	47	Philippines	98	Japan	31
Germany	4	Korea	33	Taiwan	46	Vietnam	68	China	26
Japan	3	Singapore	32	India	37	Japan	67	India	18
Thailand	3	Vietnam	29	Indonesia	22	Singapore	36	Hong Kong	17
Qatar	3	Thailand	21	Singapore	22	Korea, South	28	Malaysia	17
France	2	Hong Kong	18	Malaysia	17	Burma	27	Australia	11
Italy	2	USA	15	USA	17	Iran	26	Bangladesh	11
Belgium	1	Philippines	13	Vietnam	16	Malaysia	23	Vietnam	11
India	1	India	11	Germany	11	Australia	21	Philippines	10
Turkey	1	Malaysia	8	Hong Kong	10	Thailand	20	USA	9
UK	1	Indonesia	7	Thailand	9	Bangladesh	17	UK	8
Malaysia	1	Australia	6	Iran	8	Pakistan	16	Indonesia	7
Sri Lanka	1	Bangladesh	6	Mongolia	8	Saudi Arabia	12	Korea	7
Switzerland	1	Sri Lanka	5	Pakistan	8	United Kingdom	12	Taiwan	5
Total	625	UK	5	Philippines	7	Taiwan, China	11	Germany	4
	%	Germany	4	Australia	5	United States	10	France	2
Domestic	90	Canada	3	Egypt	3	Germany	9	México	2
Foreign	10	Mongolia	3	France	3	Sri Lanka	9	Argentina	1
		Myanmar	3	Turkey	3	Hong Kong, China	8	Austria	1
		Romania	2	UK	3	Indonesia	6	Canada	1
		Cambodia	1	Switzerland	2	Mongolia	6	Iran	1
		France	1	Spain	2	Canada	4	Italy	1
		Iran	1	Bangladesh	2	France	3	Myanmar	1
		Netherlands	1	Austria	1	Italy	2	Pakistan	1
		North Korea	1	Brazil	1	Nepal	2	Portugal	1
		Spain	1	Cambodia	1	Belgium	1	UAE	1
		Total	716	Canada	1	Cambodia	1	Total	778
			%	Italy	1	Ireland	1		%
		Domestic	46	Myanmar	1	Netherlands	1	Domestic	67
		Foreign	54	Nepal	1	Sweden	1	Foreign	33
				Netherlands	1	Switzerland	1		
				Poland	1	United Arab Emirates	1		
				Sri Lanka	1	Total	1543		
				Uzbekistan	1		%		
				Total	1206	Domestic	53		
					%	Foreign	47		
				Domestic	63				
				Foreign	37				

\*APBMT 2019 with ICBMT 2019 (International Congress of Blood and Marrow Transplantation)

\*\*APBMT 2020 with ISBMT (Indian Society for Blood & Marrow Transplantation)

\*\*\*APBMT 2021 with TSH (Thai Society of Hematology)



# Registry Committee

## APBMT Registry Committee

APBMT has long collected HSCT activity and outcome data through APBMT Data Center. To promote and accelerate the data collection, APBMT decided to establish the Registry Committee in October 2014 and it officially started operations in October 2015. APBMT Data Center was integrated into the Committee. In 2021, rules for the appointment of members in the Committee Terms changed. The rules now state that “Members are nominated by the Scientific Committee members or the Registry Committee members in each country/region, and approved by the Executive Board. The decision will be reported to the Scientific Committee members.” Four our new members joined according to this rule.

Since the Committee began the work, four important official documents have been finalized.

- Protocol
- Letter of Commitment
- Informed Consent for Patients
- Detailed Rules for Data Usage and Authorship  
(Revised version 2.0 was approved on July 16, 2020)

Based on these documents, committee members work hard:


- To perform APBMT Activity Survey and Outcome Registry annually
- To support data collection in participating countries/regions
- To manage and analyze the collected data
- To optimize the data usage
- To support clinical researches using collected data

For further achievement, members have the web conference bi-monthly.

### **[About Activity Survey]**

The APBMT Activity Survey has been performed annually since 2007 (HSCT data from 2005). This survey collects the number of transplantations sorted by the donor sources and diseases in each country/region.

The following figure shows how the data is collected.



The method of submission is different in each country/region.

As shown in the figure above, data from China, India, Iran, Japan, Korea, Malaysia, and Taiwan was submitted through their respective national registry. The Australasian Bone Marrow Transplant Recipient Registry (ABMTRR) submitted the national data for Australia and New Zealand. In Bangladesh, Indonesia, Myanmar, the Philippines, Sri Lanka, and Thailand, data was collected by a designated contact person and submitted to Data Center. Data Center has direct contact with significant transplantation centers and receives data from Hong Kong, Mongolia, Nepal, Pakistan, Singapore, and Vietnam. Data Center compiles all data collected in each of these six countries/regions, and gathered data is available for each country/region to use as national data.

The results of the Activity Survey are put on the APBMT website:

<https://www.apbmt.org/research/registry/survey>


### [About Outcome Registry]

APBMT Registry Committee and Data Center have been collecting the HSCT outcome data of each patient. The basic dataset structure is called the Least Minimum Dataset (LMD), and three methods are available for sending data to Data Center depending on

the situation in each country/region.

- The simplified Excel forms made by APBMT Data Center based on the EBMT MED-A or the CIBMTR TED
- Receiving data from CIBMTR through data transfer agreements, which were established between APBMT and CIBMTR and between APBMT and some centers that submitted Outcome Data to CIBMTR
- The electronic data capture (EDC) system using REDCap®

When the Registry/Society in participating counties/regions starts to submit HSCT outcome data to APBMT, a Non-Disclosure Agreement (NDA) is signed between APBMT and the Registry/Society when requested. In addition, APBMT Registry Committee stipulates detailed rules for data usage so that the submitted data will not be disclosed without the consent of the Committee.



\*The following countries/regions are building up their systems for submitting outcome data: Indonesia, Iran, Korea, Malaysia, and Thailand

## Registry Committee Member List

	Name	Country/Region
Chairperson	Yoshiko Atsuta	Japan
Deputy Chairpersons	Anthony Dodds	Australia/New Zealand
	Aloysius Ho	Singapore
Members	Mafruha Akter	Bangladesh
	Pheng Bora	Cambodia
	Xiao Jun Huang	China
	Liu Kaiyan	China
	Lv Meng	China
	Joycelyn Sim	Hong Kong
	Vincent Lee	Hong Kong
	Alok Srivastava	India
	Kavitha M.L	India
	Damai Santosa	Indonesia
	Amir Hamidieh	Iran
	Shinichiro Okamoto	Japan
	Yachiyo Kuwatsuka	Japan
	Joon Ho Moon	Korea
	Kim Wah Ho	Malaysia
	Batsukh Khishigjargal	Mongolia
	Aye Aye Gyi	Myanmar
	Bishesh Poudyal	Nepal
	Tasneem Farzana	Pakistan
	Marjorie Rose Bravo	Philippines
	Prasad Abeysinghe	Sri Lanka
	Devinda Jayathilake	Sri Lanka
	Bor-Sheng Ko	Taiwan
	Hui-Fen Chiang	Taiwan
	Po-Nan Wang	Taiwan
	Ming Yao	Taiwan
	Artit Ungkanont	Thailand
	Suradej Hongeng	Thailand
	Huynh Van Man	Vietnam
	Phu Chi Dung	Vietnam
Data Center	Minako Iida	Japan
	Yukari Nakao	Japan
	Hiroe Namizaki	Japan

# **Nuclear Accident Management (NAM) Committee**

## Nuclear Accident Management (NAM) Committee

The APBMT Nuclear Accident Management Committee (NAM Committee) was established at the APBMT Annual Congress in Hyderabad, India, in 2012 to:

- 1) investigate what is happening in this region and what is being done around the world in the field of a nuclear accident
- 2) facilitate cooperation with other societies such as EBMT, ASTCT, and WBMT
- 3) establish an APBMT Nuclear Accident Registry
- 4) establish a training program
- 5) prepare the standard operating procedure for the handling of the nuclear accident in our region

Since then, the NAM meeting has been held every year at the Annual Congress, and the final draft of the NAM guidelines, written by co-chairs (Drs. Velu Nair and Hyo Rak Lee), was approved by the APBMT Scientific Committee in 2020.

<https://www.apbmt.org/education/guideline-nam>

### Member List

Position	Name	Country/Region
Chair	Velu Nair	India
Chair	Hyo Rak Lee	Korea
Past Chair	Alok Srivastava	India
Past Chair	David Ma	Australia
	Mohiuddin Khan	Bangladesh
	Koichi Miyamura	Japan
	Syuuichi Taniguchi	Japan
	Khishigjargal Batsukh	Mongolia
	Aye Aye Gyi	Myanmar
	Simit Sapkota	Nepal
	Prasad Abeysinghe	Sri Lanka
	Phu Chi Dung	Vietnam
Chairman, Executive Board	Shinichiro Okamoto	Japan

# Executive Board

## Executive Board Activities

For smooth management of the international society, Executive Board members have official web conferences every month and ad-hoc web conferences when needed. The main topics discussed in the Executive Board web conferences are:

- Working together with the host country/region to prepare for each annual congress
  - Making up the scientific program
  - Nomination of speakers
  - Management of funding
- Nominating the host country for the upcoming annual congress
- Amendment of the Bylaws and membership definition
- Rulemaking for each committee
- Sponsorship contract with the third parties/companies
- Education/training of physicians/nurses involved in HSCT and cell therapy
- Collaboration with ASTCT, EBMT, WBMT, and other related societies in the field of HSCT
  - Nomination of APBMT members to the Harmonization Definition Task Force (ASTCT/EBMT)
  - Nomination of APBMT speakers for the TCT meeting, EBMT, WBMT Webinars, and EBMT COVID-19 SUMMIT
- Membership control
  - Review of membership application forms
  - Membership fees
  - Dual membership between ASTCT
- Solving the problems with advice to each committee (Registry Committee, Editorial Board of Blood Cell Therapy, Financial Committee)
- Conduct survey research if needed
  - Survey on Cancer Immunology in Asian Countries (JAPAN)
  - Survey for the presentation of “Quality and Accreditation for Cellular Therapy: A Global Perspective” (WBMT)
  - Survey for COVID-19 impacts on HSCT in 2020 (EBMT summit)
  - Antiemetics survey (Nutrition Support WG)

## Executive Board Members



**Shinichiro Okamoto**  
Chairman  
Japan



**Alok Srivastava**  
Vice Chairman  
India



**Jong-Wook Lee**  
Korea



**David Ma**  
Australia



**Amir Hamidieh**  
Iran



**William Hwang**  
Singapore



**He Huang**  
China

# **Collaboration with Other International Registries**

**WBMT**

**ASTCT**

**EBMT**

## **WBMT (Worldwide Network for Blood & Marrow Transplantation)**

APBMT is one of the first founding societies of WBMT and has collaborated with other member societies such as CIBMTR, EBMT, and WMDA to operate WBMT since 2007.

Dr. Yoshihisa Kodera (Japan) and Dr. Jeff Szer (Australia) have served as the WBMT president. Many members in APBMT played important roles in the Standing Committees in 2020: Co-chair of Education & Dissemination Committee: Yoshihisa Kodera, Co-chair of Global Emergencies/Nuclear Accident Management Committee: David Ma, Co-chair of Transplant Centre/Recipient Committee: Yoshiko Atsuta.

In addition, APBMT Data Center has submitted the Activity Survey data every year to contribute to the WBMT Global Transplant Activity Survey.

## **ASTCT (American Society for Transplantation and Cellular Therapy)**

After exchanging memorandums of understanding for dual membership on August 23, 2018, APBMT and ASTCT implemented the dual membership. APBMT members who applied for this membership could receive many benefits from ASTCT. APBMT and ASTCT will continue to proceed with the second and third collaboration projects.

## **EBMT (European Society for Blood and Marrow Transplantation)**

With the cooperation of EBMT, APBMT could set up an original booth at the annual meeting for the past few years. APBMT could exhibit the activities and contact with registered members and non-members there. With regard to a project for the establishment of the APBMT Center Standards, we could get informative advice from JACIE members.

# History of International Scientific Symposia

2021

## **October, APBMT 2021 hybrid (Thailand)**

*Presidential Symposium: Design the future of HCT Societies*

Chairpersons: S. Okamoto, A. Ungkanont

- EBMT perspective (N. Kroger)
- ASTCT perspective (S. Davies)
- WBMT perspective (H. Greinix)
- APBMT perspective (S. Okamoto)

## **July, FACT/WBMT Webinar**

*Quality and Accreditation for Cellular Therapy: A Global Perspective*

- Establishing an HSCT Program: Essential Requirements (D. Niderwieser)
- Development of a Quality Program in the Asia-Pacific Region (A. Srivastava)
- FACT-JACIE Accreditation in Latin America (C. Bachier)

## **June, EBMT Summit on COVID-19**

*Clinical Impact and management in HSCT patient 1, Activity impact and clinical outcome*

Chairs: P. Ljungman, M. Mikulska

- EBMT experience (P. Ljungman)
- USA experience: COVID19: Clinical Experience at Memorial Sloan Kettering Cancer Center (G. Papanicolau)
- Asian Pacific BM Society experience (APBMT) (W. Hwang)

## **April, WBMT/EBMT Webinar**

*Haplo-Identical HSCT, Methods and Practices Around the Globe*

Moderators: H. Greinix, N. Kröger

- Haploidentical HSCT practice in Europe (A. Bacigalupo)
- Haploidentical HSCT practice in Asia (XJ. Huang)
- Haploidentical HSCT practice in North America (L. Luznik)

## **March, EBMT (virtual)**

*Joint session ASTCT/CIBMTR/APBMT: Transplantation and Cell Therapy During Pandemics*

Co-Charis: N. Kröger, S Davies, M. Riches, A. Srivastava

- US Experience: Pandemics and Transplantation/Cell therapy (A. Waghmare)
- The CIBMTR COVID Experience: Challenges for research and how COVID has changed transplant practice (M. Riches)

- The IDWP-EBMT COVID 19 Experience (R. Cámara)
- Asian-Pacific Experience: Allo-HSCT and CAR-T cell treatment during COVID 19 pandemic (Y. Hu)

### **February, ASTCT (Digital Experience)**

*WBMT Concurrent: Transplant During a Worldwide Crisis: Lessons Learned Across the World*

Co-Chairs: W. Saber, M. Aljurf

- The Latin American Bone Marrow Transplantation Group (LABMT) Experience (A. Seber)
- HSCT Challenges and Solutions Under COVID-19: The Experience from China (X. Huang)
- The Eastern Mediterranean Blood and Marrow Transplantation (EMBT) Group Experience (RE. Fakih)

## **2020**

### **October, APBMT 2020 virtual (India)**

*Presidential Symposium on HSCT and Covid-19*

Chairpersons: S. Okamoto, N. Kroeger, A. Srivastava

Moderator: S. Damodar

- HSCT in the Covid-19 Era- the Chinese Experience (H. Huang)
- Practice of HSCT in North America in COVID-19 Era (N. Majhail)
- Practice of HSCT in Europe in COVID-19 Era (P. Ljungman)
- Managing HSCTs in the context of COVID-19 pandemic - A LMIC perspective (S. Damodar)

### **May, WBMT Live Webinar (Online)**

*COVID-19 and stem cell transplantation, a Worldwide perspective:*

Moderators: Y Kodera, S Galeano

- Management of donors during the pandemic (F. Alfraih)
- Transplant recipients; COVID-19 guidelines and real-world (C. Machado)
- Chinese experience (H. Huang)
- Data from the EBMT registry during COVID-19 (P. Ljungman)
- Chimeric Antigen Receptor T Cell Therapy during COVID-19 (MA. Perales)

## **2019**

### **August, APBMT (Korea)**

*ASTCT/EBMT/WBMT/APBMT Joint Session:*

Co-Chairs: JW Lee, S. Okamoto

- GvHD Prophylaxis with Post Cy after Haplo-Identical, Matched Unrelated and HLA-Identical Sibling Transplantation (N. Kroger)
- Future Changes in Stem Cell Transplantation and Cellular Therapy: Safer, Less Toxic and Less Costly Approaches (D. Weisdorf)
- Novel Approaches for Treating and Preventing GvHD (JF DiPersio)
- Design the Future of Hematopoietic Cell Transplantation (HCT) in Asia-Pacific Countries/Regions (S. Okamoto)

## 2018

### **November, APBMT (Taiwan)**

*ASBMT / EBMT / WBMT / APBMT Joint Symposium: Past, Now, and Future of Hematopoietic Stem Cell Transplantation*

Co-Chairs: M. Yao, S. Okamoto

- Hematopoietic Stem Cell Transplantation: Where we have come from and where do we go? (J. Gajewski)
- Past, now and future of hematopoietic stem cell transplantation (EBMT prospective) (N. Kroger)
- How does the past predict the future of allogeneic transplantation: lessons for the field? (D. Weisdorf)
- How the APBMT is facing the challenge (S. Okamoto)

### **September, The 5th WBMT Workshop (Beijing, China)**

*International Experience and Data Sharing to Improve Access and Outcomes of Transplantation*

1. Importance of creating the HSCT global outcome registration system
  - Global perspective of HSCT & registration (J. Szer)
  - WBMT Global Survey & registration (D. Niederwieser)
  - CIBMTR perspective of HSCT and registration (M Pasquini)
  - HSC Donor Registries: Challenges and Perspectives (C. Muller)
  - APBMT perspective: Importance of Outcome Data Sharing in Asian Pacific Region (Y. Kodera)
  - Current Activity Survey in the AP region (M. Iida)
  - Outcome Registry Current Status and future perspectives (Y. Atsuta)
  - Chinese perspective of HSCT and Activity Surveys; Difficulties in Data collection (XJ. Huang)
2. International Standards and Accreditation
  - Steps towards international accreditation: Lessons learned (S. Okamoto)
  - Addressing unproven cellular therapies (M. Koh)

### **April, WBMT/AfBMT (Morocco)**

*First Meeting of the African Blood and Marrow Transplantation Group: SCT in bone marrow failure*

Co-Chairs: N. Novitzky, N. Khoubila

- Recent Progress in Diagnosis and Treatment of Inherited Bone Marrow Failure (S. Kojima)
- Acquired (S. Osman Ahmed)

## **2017**

### **October, APBMT (Iran)**

*APBMT / WBMT Joint Session: Transplantation reports in the Asian pacific region & the progress of BMT in the world and Asian pacific region*

Co-Chairs: A. Ghavamzadeh, S. Okamoto

- The progress of BMT in the Islamic Republic of Iran (A. Ghavamzadeh)
- The report of transplantation in all 15 BMT centers of Iran in the last five years (A. Hajifathali)
- The current status and future challenges of the Asia-Pacific Blood and Marrow Transplantation Group (APBMT) (S. Okamoto)
- The history, current status and future trends of WBMT (Y. Kodera)
- The report of transplantation in China five recent years (H. Huang)
- The advance of HSCT after the enforcement of “The Act for Appropriate Provision of Hematopoietic Stem Cells to be Used in Transplantations” in Japan (Y. Kodera)
- Outcome of autologous hematopoietic stem cell transplants for multiple myeloma in a single center in Sri Lanka (L. Gooneratne)
- The report of transplantation in Malaysia in five recent years (OT. Chuan)

# **Blood Cell Therapy**

The official journal of APBMT



# Blood Cell Therapy

The official journal of APBMT

Blood Cell Therapy is the official journal of Asia-Pacific Blood and Marrow Transplantation Group. We have published it since October 2018 and issue quarterly.



Home > Archive

## Archive

Volume 3 (2020)

### Volume 3 (2020)

Issue 1 Issue 2 Issue 3 **Issue 4**

Case Report

**Post-HSCT relapsed precursor B-cell ALL successfully salvaged by BITE followed by consolidation CART cell therapy: A report of two cases**

Wai-Han Huang, Chun-Rong Tong, Tong Wu, Yun-Chu Lin, Chi-Cheng Li

Volume 3 (2020) Issue 4 No.1 Pages 71-73

Submitted: March 25, 2020 Accepted: June 12, 2020 Published online: August 4, 2020  
Issued online: November 25, 2020 DOI: <https://doi.org/10.31547/bct.2020.002>

Case Report

**Salvage Transplantation with Cord Blood for Graft Rejection of Peripheral Blood Stem Cells due to Donor Specific Antibody**

Maria Regina Pelobello de Leon, Shuichiro Takahashi, Masahiro Onozawa, Makoto Ito, Manabu Nakano, Hajime Senjo, Masahiro Chiba, Hiroyuki Ohigashi, Emi Yokoyama, Junichi Sugita, Daigo Hashimoto, Takanori Teshima

Volume 3 (2020) Issue 4 No.2 Pages 74-77

Submitted: May 18, 2020 Accepted: June 25, 2020 Published online: August 21, 2020  
Issued online: November 25, 2020 DOI: <https://doi.org/10.31547/bct.2020.004>

## News

February 25, 2021

**Volume 4 (2021) Issue 1 No.3**

Pharmacokinetics of anti-thymocyte globulin in a patient with severe aplastic anemia treated with allogeneic bone marrow transplantation from a matched unrelated donor...

February 25, 2021

**Volume 4 (2021) Issue 1 No.2**

Dynamics of Epstein-Barr virus after cord blood transplantation: A nationwide survey in Japan...

February 25, 2021

**Volume 4 (2021) Issue 1 No.1**

Autologous stem cell transplantation (ASCT) outcome for multiple myeloma in a tertiary referral centre in Malaysia...

> Past News



Online ISSN : 2432-7026

**Online ISSN: 2432-7026**

**Journal homepage: <https://bct.apbmt.org/>**

**Aims and scope:** Blood Cell Therapy is an international journal publishing peer-reviewed original and review articles in the field of all aspects of hematopoietic cell transplantation and cell therapy. Not only clinical research but also basic research relevant to cell therapy are covered. The scope of our journal encompasses wide variety of clinical or basic topics including:

- Results of trials with new protocols
- Transplant-related complications
- Transplant outcome studies dealing with QOL, psychology, economy or regional characteristics
- Prognostic analysis based on biomarkers
- Translational research
- Transplantation immunology
- Cellular or gene therapy

## Submission status of Blood Cell Therapy as of December 31, 2021

	2017	2018	2019	2020	2021
<b>Total Submitted</b>	2	11	17	23	25
<b>Total Decided</b>					
Accept	1	9	12	17	21
Reject	1	2	3	6	3
Ongoing	0	0	0	0	1
<b>Acceptance Rate</b>	50%	82%	71%	74%	(84%)
<b>Article type</b>					
State of the Art					7
Original Article	1	3	5	14	8
Review Article	0	3	2	1	2
Case Report	1	4	4	6	6
Short Communication	0	1	2	1	2
Survey Report	0	0	4		
Guideline				1	

## Authors by country/region

	2017	2018	2019	2020	2021	Total
Australia		1	1		1	3
Bangladesh			1			1
Canada				1		1
China		1		1		2
India			2	6	4	12
Indonesia	1		1			2
Japan	1	7	6	8	6	28
Korea		1	1		1	3
Malaysia			1	2	1	4
Myanmar			1			1
Pakistan				1		1
Philippines				1	3	4
Singapore			1	2	2	5

Sri Lanka		1	1
Taiwan		1	1
Thailand			1 1
Vietnam			1 1
Germany			1 1
United Kingdom	1		1
United States		1	1

### Editorial Award of Blood Cell Therapy 2020

Minako Iida	Late mortality and causes of death among long-term survivors after autologous hematopoietic stem cell transplantation Volume 3 (2020) Issue 1 No.3 Pages 11-17 <a href="https://doi.org/10.31547/bct-2019-011">https://doi.org/ 10.31547/bct-2019-011</a>
Takahiko Sato	Day 0 bone marrow pathology of allogeneic hematopoietic stem cell transplantation is a novel prognostic factor in myeloid malignancies Volume 3 (2020) Issue 4 No.4 Pages 84-91 <a href="https://doi.org/10.31547/bct-2020-007">https://doi.org/ 10.31547/bct-2020-007</a>
Yoo Jin Lee	Treatment of relapsed acute leukemia by Ara C plus donor lymphocyte infusion using CD34+ cells reserved at the time of allogeneic transplantation Volume 3 (2020) Issue 2 No.2 Pages 22-31 <a href="https://doi.org/10.31547/bct-2019-015">https://doi.org/ 10.31547/bct-2019-015</a>

## Editorial Board Member List

Name	Commission	Country
Yoshiki Akatsuka	Editor-in-Chief	Japan
Tatsuo Ichinohe	Deputy Editor-in-Chief	Japan
Jeffrey Szer	Associate Editors	Australia
David Yeung		Australia
Haowen Xiao		China
Navin Khattry		India
Auro Viswabandya		India
Maryam Behfar		Iran
Ayami Yoshimi		Germany /Japan
Satoshi Takahashi		Japan
Junya Kanda		Japan
Shinichiro Okamoto		Japan
Jae Yong Kwak		Korea
Hee-Je Kim		Korea
Mickey Boon Chai Koh		Singapore
William YK Hwang		Singapore
Mei Zhang		China
Yuqian Sun		China
Alok Srivastava		India
Amir Hamidieh	Iran	
Mahmoud Aljurf	Saudi Arabia	
Daniel Weisdorf	USA	
Minako Iida	Editorial Office	Japan
Yukari Nakao	Editorial Office	Japan
Hiroe Namizaki	Editorial Office	Japan

\*random order

### Information for Submission

Manuscript submission rules for Authors : [https://bct.apbmt.org/for\\_authors/](https://bct.apbmt.org/for_authors/)

Editorial Policies : [https://bct.apbmt.org/editorial\\_policies/](https://bct.apbmt.org/editorial_policies/)

Guide for Reviewers : [https://bct.apbmt.org/for\\_reviewers/](https://bct.apbmt.org/for_reviewers/)

Submission : <https://mc.manuscriptcentral.com/bct>

## List of the Accepted Articles (As of November 25, 2021)

### *Original Article*

#### **Monitoring of citrulline and diamine oxidase levels as biomarkers for intestinal mucositis during early-phase hematopoietic cell transplantation**

Noriyasu Fukushima<sup>1,2,3</sup>, Satoshi Tomiyasu<sup>2</sup>, Yoshinori Uji<sup>2</sup>, Masako Yokoo<sup>3</sup>, Takero Shindo<sup>3</sup>, Yasushi Kubota<sup>3</sup>,

Toshihiko Ando<sup>3</sup>, Kensuke Kojima<sup>3</sup>, Eisaburo Sueoka<sup>4</sup>, Tatsuo Ichinohe<sup>1</sup>, Shinya Kimura<sup>3</sup>

<sup>1</sup>Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan. <sup>2</sup>Department of Medical Science Technology, School of Health Sciences at Fukuoka,

International University of Health and Welfare, Okawa, Japan <sup>3</sup>Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan. <sup>4</sup>Department of Laboratory Medicine, Faculty of Medicine, Saga University, Saga, Japan.

Blood Cell Therapy Vol.1 Issue.1 No.1 Pages 1-8

Submitted: December 19, 2017 Accepted: July 7, 2018 Published online: August 29, 2018

DOI:<https://doi.org/10.31547/bct-2017-002>

### *Review Article*

#### **Recent advances and current challenges in allogeneic stem cell transplantation in patients with acquired severe aplastic anemia**

Sung-Eun Lee and Jong Wook Lee

Department of Hematology, Catholic Blood and Marrow Transplantation Center, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

Blood Cell Therapy Vol.1 Issue.1 No.2 Pages 9-17

Submitted: March 6, 2018 Accepted: May 19, 2018 Published online: August 29, 2018

DOI:<https://doi.org/10.31547/bct-2018-001>

### *Review Article*

#### **Recent progress in improving the safety and efficacy of chimeric antigen receptor T cell therapy**

Yingying Yang, Yongxian Hu, Jiasheng Wang, He Huang

Zhejiang University School of Medicine First Affiliated Hospital

Blood Cell Therapy Vol.1 Issue.1 No.3 Pages 18-27

Submitted: April 12, 2018 Accepted: July 7, 2018 Published online: August 29, 2018

DOI:<https://doi.org/10.31547/bct-2018-003>

### *Case Report*

## **Primary CNS post-transplant lymphoproliferative disorder following haplo- identical HSCT using post-transplant high-dose cyclophosphamide**

Masako Toyosaki<sup>1</sup>, Makoto Onizuka<sup>1</sup>, Jun Amaki<sup>1</sup>, Sawako Shiraiwa<sup>1</sup>, Yasuyuki Aoyama<sup>1</sup>, Shinichiro Machida<sup>1</sup>, Hidetsugu Kawai<sup>1</sup>, Hiromichi Murayama<sup>1</sup>, Daisuke Ogiya<sup>1</sup>, Keiko Matsui<sup>1</sup>, Shohei Kawakami<sup>1</sup>, Kaito Harada<sup>1</sup>, Yusuke Kondo<sup>2</sup>, Kenichi Hirabayashi<sup>2</sup>, Naoya Nakamura<sup>2</sup>, Yoshiaki Ogawa<sup>1</sup>, Hiroshi Kawada<sup>1</sup>, Kiyoshi Ando<sup>1</sup>

<sup>1</sup>Division of Hematology and Oncology, Department of Medicine, Tokai University School of Medicine, Kanagawa, Japan, <sup>2</sup> Department of Pathology, Tokai University School of Medicine, Kanagawa, Japan

Blood Cell Therapy Vol.2 Issue.1 No.1 Pages 1-4

Submitted: May 8, 2018 Accepted: August 9, 2018 Published online: October 26, 2018

DOI:<https://doi.org/10.31547/bct-2018-004>

### *Case Report*

## **Successful allogeneic peripheral blood stem cell transplantation for an aggressive variant of T-cell large granular-lymphocyte leukemia: A case report**

Kazuhito Suzuki<sup>1,2</sup>, Kaichi Nishiwaki<sup>1,2</sup>, Jiro Minami<sup>2</sup>, Hidekazu Masuoka<sup>1,2</sup>, Mitsuji Katori<sup>1,2</sup>, Hiroki Yokoyama<sup>1,2</sup>, Hideki Uryu<sup>1,2</sup>, Shingo Yano<sup>2</sup>

<sup>1</sup>Division of Clinical Oncology/Hematology, The Jikei University Kashiwa Hospital, <sup>2</sup>Division of Clinical Oncology/Hematology, The Jikei University School of Medicine

Blood Cell Therapy Vol.2 Issue.1 No.2 Pages 5-8

Submitted: May 20, 2018 Accepted: September 5, 2018 Published online: October 26, 2018

DOI:<https://doi.org/10.31547/bct-2018-006>

### *Case Report*

## **Gastric antral vascular ectasia in a pediatric patient with neuroblastoma who underwent tandem stem cell transplantation**

Yumiko Sugishita, Shohei Yamamoto, Ryota Kaneko, Naoko Okamoto, Masaya Koganesawa, Sachio Fujita, Kosuke Akiyama, Ryosuke Matsuno, Daisuke Toyama, Keiichi Isoyama

Department of Pediatrics, Showa University Fujigaoka Hospital, Japan

Blood Cell Therapy Vol.2 Issue.1 No.3 Pages 9-11

Submitted: August 24, 2018 Accepted: October 2, 2018 Published online: January 15, 2019

DOI:<https://doi.org/10.31547/bct-2018-007>

### ***Review Article***

## **Autologous hematopoietic stem cell transplant for autoimmune diseases: evolution, evidence of efficacy, and real-world economics**

Massey, Jennifer C.<sup>1,2,3</sup>, Moore, John J.<sup>2,3,4</sup>, Milliken, Samuel T.<sup>4</sup>, Ma, David D. F.<sup>2,3,4,5</sup>

<sup>1</sup>Department of Neurology, St Vincent's Hospital Sydney, Australia, <sup>2</sup>Blood, Stem Cell and Cancer Research Program, St Vincent's Centre for Applied Medical Research, Sydney, Australia, <sup>3</sup>St Vincent's Clinical School, Faculty of Medicine, University of NSW, Sydney, Australia, <sup>4</sup>Department of Haematology and Bone Marrow Transplant, St Vincent's Hospital Sydney, Australia, <sup>5</sup>Corresponding author

Blood Cell Therapy Vol.2 Issue.2 No.1 Pages 12-21

Submitted: September 14, 2018 Accepted: October 23, 2018 Published online: April 1, 2019

DOI:<https://doi.org/10.31547/bct-2018-009>

### ***Original Article***

## **Kinetics of neutrophil engraftment in allogeneic stem cell transplantation**

Akihisa Kawajiri<sup>1</sup>, Shigeo Fuji<sup>1,2</sup>, Yoshihiro Inamoto<sup>1</sup>, Saiko Kurosawa<sup>1</sup>, Takashi Tanaka<sup>1</sup>, Ayumu Ito<sup>1</sup>, Keiji Okinaka<sup>1</sup>, Sung-Won Kim<sup>1</sup>, Takahiro Fukuda<sup>1</sup>

<sup>1</sup>Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan

<sup>2</sup>Department of Hematology, Osaka International Cancer Institute, Osaka, Japan

Blood Cell Therapy Vol.2 Issue.2 No.2 Pages 22-30

Submitted: October 20, 2018 Accepted: January 23, 2019 Published online: April 1, 2019

DOI:<https://doi.org/10.31547/bct-2018-011>

### ***Short Communication***

## **A decade of excellent transplant survival in children with inherited metabolic diseases: A report from a single metabolic transplant centre in Europe**

Su Han Lum<sup>1</sup>, Andrew Will<sup>1</sup>, Heather J Church<sup>2</sup>, Jean Mercer<sup>2</sup>, Karen L Tylee<sup>2</sup>, Kay Poulton<sup>3</sup>, Wendy Odgen<sup>4</sup>, Helena Lee<sup>3</sup>, Alison Logan<sup>3</sup>, Mary Coussons<sup>1</sup>, Tasneem Khalids<sup>5</sup>, Denise Bonney<sup>1</sup>, Stewart Rust<sup>6</sup>, Prashant Hiwarkar<sup>1</sup>, Simon A Jones<sup>2</sup>, Robert F Wynn<sup>1</sup>

<sup>1</sup>Department of Pediatric Blood and Marrow Transplant, Royal Manchester Children's Hospital, UK, <sup>2</sup>Manchester Center for Genomic Medicine, St Mary's Hospital, Manchester, UK, <sup>3</sup>Transplantation Laboratory, Manchester Royal Infirmary, Manchester, UK, <sup>4</sup>Therapeutic Stem Cell Laboratory, Royal Manchester Children's Hospital, Manchester, UK, <sup>5</sup>Department of Pharmacy, Royal Manchester Children's Hospital, Manchester, UK, <sup>6</sup>Pediatric Psychosocial Department, Royal Manchester Children's Hospital, Manchester, UK

Blood Cell Therapy Vol.2 Issue.2 No.3 Pages 31-35

Submitted: October 23, 2018 Accepted: February 8, 2019 Published online: May 10, 2019

DOI:<https://doi.org/10.31547/bct-2018-012>

### ***Case Report***

## **Role of hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia: a report of 2 unique cases**

Yadanar Lwin<sup>1</sup>, David Ma<sup>1,2</sup>

<sup>1</sup>Department of Haematology and BM Transplant, St Vincent's Hospital Sydney, NSW, Australia, <sup>2</sup>St Vincent's Clinical School, Faculty of Medicine, the University of New South Wales

Blood Cell Therapy Vol.2 Issue.3 No.1 Pages 36-38

Submitted: March 25, 2019 Accepted: April 5, 2019 Published online: June 7, 2019

DOI:<https://doi.org/10.31547/bct-2019-001>

### ***Original Article***

## **Predictors of parental distress during acute phase of pediatric hematopoietic stem cell transplantation in Japan: A multicenter prospective study**

Shohei Nakajima<sup>1</sup>, Ami Setoyama<sup>1</sup>, Iori Sato<sup>1</sup>, Tomoko Fukuchi<sup>2</sup>, Harumi Tanaka<sup>2</sup>, Masami Inoue<sup>3</sup>, Kentaro Watanabe<sup>4</sup>, Katsuyoshi Koh<sup>4</sup>, Junko Takita<sup>5</sup>, Mika Tokuyama<sup>6</sup>, Kenichiro Watanabe<sup>6</sup>, Kiyoko Kamibeppu<sup>1</sup>

<sup>1</sup>Department of Family Nursing, Division of Health Sciences and Nursing, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, <sup>2</sup>Department of Nursing, Osaka Women's and Children's Hospital, Osaka, Japan, <sup>3</sup>Department of Hematology/Oncology, Osaka Women's and Children's Hospital, Osaka, Japan, <sup>4</sup>Department of Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan, <sup>5</sup>Department of Pediatrics, The University of Tokyo Hospital, Tokyo, Japan, <sup>6</sup>Department of Hematology and Oncology, Shizuoka Children's Hospital, Shizuoka, Japan.

Blood Cell Therapy Vol.2 Issue.3 No.2 Pages 39-49

Submitted: October 18, 2018 Accepted: April 15, 2019 Published online: June 18, 2019

DOI:<https://doi.org/10.31547/bct-2018-010>

### ***Survey Report***

## **Country Report: The Report of Transplant Activity and Outcome During the First 12 Months at the First National Hematopoietic Stem Cell Transplant Center in Sri Lanka**

P Abeyasinghe<sup>1</sup>, L Morawaka<sup>2</sup>, S Gunasekara<sup>1</sup>, S Suresh<sup>1</sup>, PWDCC Jayathilake<sup>1</sup>, PHSP Udara<sup>1</sup>, PPR Siriwardena<sup>1</sup>, S Milliken<sup>3</sup>, J Moore<sup>3</sup>, DDF Ma<sup>3</sup>

<sup>1</sup>National Cancer Institute, Sri Lanka, <sup>2</sup>National Blood Transfusion Service, Sri Lanka, <sup>3</sup>Department of Haematology and BM Transplantation, St. Vincent's Hospital Sydney, NSW, Australia

Blood Cell Therapy Vol.2 Issue.4 No.1 Pages 50-53

Submitted: May 29, 2019 Accepted: August 25, 2019 Published online: November 25, 2019

DOI:<https://doi.org/10.31547/bct-2019-007>

### ***Survey Report***

## **Transplant Programs in APBMT: Blood and Marrow Transplant Activity Report from Myanmar APBMT Meeting 2018, Taiwan**

Aye Aye Gyi<sup>1</sup>, Htun Lwin Nyein<sup>2</sup>, Thida Aung<sup>3</sup>, Rai Mra<sup>4</sup>

<sup>1</sup>Department of Clinical Haematology, North Okkalapa General and Teaching Hospital, University of Medicine 2, Yangon, Myanmar, <sup>2</sup>Department of Clinical Haematology, Yangon General Hospital, Yangon, <sup>3</sup>National Blood Center, Yangon, <sup>4</sup>Myanmar Society of Haematology, Myanmar Medical Association

Blood Cell Therapy Volume 2 (2019) Issue 4 No.2 Pages 54-57

Submitted: June 18, 2019 Accepted: September 9, 2019 Published online: November 25, 2019

DOI: <https://doi.org/10.31547/bct-2019-008>

### ***Review Article***

## **Expansion of Haematopoietic Stem and Progenitor Cells: Paving the Way for Next- Generation Haematopoietic Stem Cell Transplantation**

Sudipto Bari<sup>1,3</sup>, Paul Chong<sup>1</sup>, William Ying Khee Hwang<sup>1,2,3</sup>

<sup>1</sup>National Cancer Centre Singapore, <sup>2</sup>Department of Haematology, Singapore General Hospital, Singapore, <sup>3</sup>Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore

Blood Cell Therapy Volume 2 (2019) Issue 4 No.3 Pages 58-67

Submitted: March 29, 2019 Accepted: September 18, 2019 Published online: November 25, 2019

DOI: <https://doi.org/10.31547/bct-2019-004>

### ***Survey Report***

## **Autologous stem cell transplant program in 2016–country report from Bangladesh**

Mafruha Akter<sup>1</sup>, Mohiuddin Ahmed Khan<sup>1</sup>, Bimalangshu R Dey<sup>2</sup>

<sup>1</sup>BMT Unit, Department of Hematology, Dhaka Medical College Hospital (DMCH), <sup>2</sup>Massachusetts General Hospital (MGH), Harvard Medical School, Boston, USA

Blood Cell Therapy Volume 3 (2020) Issue 1 No.1 Pages 1-5

Submitted: May 27, 2019 Accepted: November 18, 2019 Published online: February 25, 2020

DOI: <https://doi.org/10.31547/bct-2019-006>

### ***Case Report***

## **Successful treatment strategy in incorporating mogamulizumab and cord blood transplantation in aggressive adult T-cell leukemia-lymphoma: a case report**

Keiichi Nakata<sup>1</sup>, Shigeo Fujii<sup>1</sup>, Midori Koike<sup>1</sup>, Yuma Tada<sup>1</sup>, Hiroaki Masaie<sup>1</sup>, Hitoshi Yoshida<sup>1</sup>, Eri Watanabe<sup>2</sup>, Seiichiro Kobayashi<sup>3</sup>, Arinobu Tojo<sup>4</sup>, Kaoru Uchimaru<sup>4</sup>, Jun Ishikawa<sup>1</sup>

<sup>1</sup>Department of Hematology, Osaka International Cancer Institute, Osaka, Japan, <sup>2</sup>Department of IMSUT Clinical Flow Cytometry Laboratory, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan, <sup>3</sup>Division of

Molecular Therapy, Institute of Medical Science, The University of Tokyo, Tokyo, Japan, <sup>4</sup>Department of Hematology/Oncology, Research Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan  
Blood Cell Therapy Volume 3 (2020) Issue 1 No.2 Pages 6-10  
Submitted: August 27, 2019 Accepted: December 5, 2019 Published online: February 25, 2020  
DOI: <https://doi.org/10.31547/bct-2019-012>

### *Original Article*

## **Late mortality and causes of death among long-term survivors after autologous hematopoietic stem cell transplantation**

Minako Iida<sup>1</sup>, Hideki Nakasone<sup>2</sup>, Takuya Yamashita<sup>3</sup>, Masami Inoue<sup>4</sup>, Yasushi Ishida<sup>5</sup>, Hitoji Uchiyama<sup>6</sup>, Yuta Katayama<sup>7</sup>, Toshihiro Miyamoto<sup>8</sup>, Satoshi Yoshioka<sup>9</sup>, Souichi Shiratori<sup>10</sup>, Takehiko Mori<sup>11</sup>, Masashi Sawa<sup>12</sup>, Yasuhiro Sugio<sup>13</sup>, Takahiro Fukuda<sup>14</sup>, Tatsuo Ichinohe<sup>15</sup>, Yoshiko Atsuta<sup>16</sup>, Yoshihiro Inamoto<sup>14</sup>, for the Late Effect and Quality of Life Working Group of the Japan Society for Hematopoietic Cell Transplantation

<sup>1</sup>Department of Promotion for Blood and Marrow Transplantation, Aichi Medical University School of Medicine, Nagakute, Japan, <sup>2</sup>Division of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Japan, <sup>3</sup>Department of Hematology, St. Luke's International Hospital, Tokyo, Japan, <sup>4</sup>Department of Hematology/Oncology, Osaka Women's and Children's Hospital, Osaka, Japan, <sup>5</sup>Department of Pediatrics, Ehime Prefectural Central Hospital, Matsuyama, Japan, <sup>6</sup>Department of Hematology, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan, <sup>7</sup>Department of Hematology, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Hiroshima, Japan, <sup>8</sup>Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan, <sup>9</sup>Department of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan, <sup>10</sup>Department of Hematology, Hokkaido University Hospital, Sapporo, Japan, <sup>11</sup>Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan, <sup>12</sup>Department of Hematology and Oncology, Anjo Kosei Hospital, Anjo, Japan, <sup>13</sup>Department of Internal Medicine, Kitakyushu City Hospital Organization, Kitakyushu Municipal Medical Center, Kitakyushu, Japan, <sup>14</sup>Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan, <sup>15</sup>Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan, <sup>16</sup>Japanese Data Center for Hematopoietic Cell Transplantation/Department of Healthcare Administration, Nagoya University Graduate School of Medicine, Nagoya, Japan

Blood Cell Therapy Volume 3 (2020) Issue 1 No.3 Pages 11-17

Submitted: October 18, 2018 Accepted: December 14, 2019 Published online: February 25, 2020  
DOI: <https://doi.org/10.31547/bct-2019-011>

### *Case Report*

## **Haploidentical hematopoietic stem cell transplantation with one-day posttransplant cyclophosphamide and anti-thymocyte globulin for graft failure**

Hiroshi Imanaga<sup>1</sup>, Takanori Ohta<sup>2</sup>, Seido Oku<sup>2</sup>, Yasuhiro Sugio<sup>2</sup>, Yuju Ohno<sup>2</sup>

<sup>1</sup>Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan,

<sup>2</sup>Department of Internal Medicine, Kitakyushu Municipal Medical Center, Fukuoka, Japan

Blood Cell Therapy Volume 3 (2020) Issue 2 No.1 Pages 18-21

Submitted: July 19, 2019 Accepted: December 15, 2019 Published online: April 21, 2020

DOI: <https://doi.org/10.31547/bct-2019-009>

### ***Original Article***

## **Treatment of relapsed acute leukemia by Ara C plus donor lymphocyte infusion using CD34+ cells reserved at the time of allogeneic transplantation**

Lee YJ<sup>1,2</sup>, Back DW<sup>1,2</sup>, Cho HC<sup>1,2</sup>, Moon JH<sup>1,2</sup>, Sohn SK<sup>1,2</sup>

<sup>1</sup>Division of Hematology-Oncology, Department of Internal Medicine, Kyungpook National University Hospital, Daegu, Republic of Korea, <sup>2</sup>School of Medicine, Kyungpook National University, Daegu, Republic of Korea

Blood Cell Therapy Volume 3 (2020) Issue 2 No.2 Pages 22-31

Submitted: October 2, 2019 Accepted: December 24, 2019 Published online: April 21, 2020

DOI: <https://doi.org/10.31547/bct-2019-015>

### ***Short Communication***

## **Real-world outcomes of stem cell transplantation for severe aplastic anemia: A single-center experience in Northern India**

Dharma Choudhury<sup>1</sup>, Meet Kumar<sup>1</sup>, Sanjeev Sharma<sup>1</sup>, Vipin Khandelwal<sup>1</sup>, Divya Doval<sup>1</sup>, Tina Dadu<sup>2</sup>, Rasika Setia<sup>3</sup>, Anil Handoo<sup>2</sup>

<sup>1</sup>Department of Hematology and BMT, BLK Super Specialty Hospital, New Delhi, <sup>2</sup>Department of Hematology, BLK Super Specialty Hospital, New Delhi, <sup>3</sup>Department of Transfusion Medicine, Super Specialty Hospital, New Delhi

Blood Cell Therapy Volume 3 (2020) Issue 2 No.3 Pages 32-36

Submitted: December 16, 2019 Accepted: January 31, 2020 Published online: May 25, 2020

DOI: <https://doi.org/10.31547/bct-2019-018>

### ***Review Article***

## **Hematopoietic Stem Cell Transplantation, Where Have We Come and Where Do We Go**

James Gajewski

Hebei Yanda Lu Daopei Hospital (consultant), China

Blood Cell Therapy Volume 3 (2020) Issue 3 No.1 Pages 37-43

Submitted: October 4, 2019 Accepted: January 31, 2020 Published online: May 25, 2020

DOI: <https://doi.org/10.31547/bct-2019-016>

### ***Survey Report***

## **Evolution of Hematopoietic Stem Cell Transplant Programs in Malaysia**

Norashikin Saidon<sup>1</sup>, Nur Adila Anuar<sup>2</sup>, Chang Kian Meng<sup>3</sup>, Ong Tee Chuan<sup>4</sup>, Tan Sen Mui<sup>4</sup>, Gan Gin Gin<sup>2</sup>, Fadilah

SAW<sup>5</sup>, Hany Ariffin<sup>6</sup>, Lin Hai Peng<sup>7</sup>, Chan Lee Lee<sup>7</sup>, Alan Teh<sup>7</sup>, Bee Ping Chong<sup>2</sup>

<sup>1</sup>Faculty of Medicine, Sungai Buloh, Universiti Teknologi MARA, Malaysia, <sup>2</sup>Hematology Unit, University of Malaya Medical Center, Malaysia, <sup>3</sup>Sunway Medical Center, Malaysia, <sup>4</sup>Hematology Department, Hospital Ampang, Malaysia, <sup>5</sup>Department of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Malaysia, <sup>6</sup>Department of Pediatrics, University of Malaya Medical Center, Malaysia, <sup>7</sup>Subang Jaya Medical Center, Malaysia

Blood Cell Therapy Volume 3 (2020) Issue 3 No.2 Pages 44-47

Submitted:December 3, 2019 Accepted:March 6, 2020 Published online:June 10, 2020

DOI:<https://doi.org/10.31547/bct-2019-017>

### ***Original Article***

## **High Overall and GVHD-Free Survival in Patients with Aplastic Anemia Receiving *in vivo* T-cell Depletion Transplants and Long-Term Complications**

Maria Queralt Salas MD<sup>1,2,3</sup>, Eshetu G. Atenafu<sup>4</sup>, Wilson Lam MD<sup>1,2</sup>, Arjun Datt Law MD<sup>1,2</sup>, Dennis(Dong Hwan)Kim MD<sup>1,2</sup>, Fotios V. Michelis MD<sup>1,2</sup>, Zeyad Al-Shaibani MD<sup>1,2</sup>, Armin Gerbitz MD<sup>1,2</sup>, Jeffrey Howard Lipton MD<sup>1,2</sup>, Auro Viswabandya MD<sup>1,2</sup>, Jonas Mattsson MD<sup>1,2</sup>, Vikas Gupta MD<sup>1</sup>, Rajat Kumar MD<sup>1,2</sup>

<sup>1</sup>University of Toronto, Dept of Medicine, Section of Medical Oncology and Hematology, <sup>2</sup>Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada, <sup>3</sup>Hematology Department, Institut Català d'Oncologia-Hospitalet, IDIBELL, Barcelona, Spain, <sup>4</sup>Department of Biostatistics, Princes Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada

Blood Cell Therapy Volume 3 (2020) Issue 3 No.3 Pages 48-58

Submitted:February 26, 2020 Accepted:May 24, 2020 Published online:July 14, 2020

DOI:<https://doi.org/10.31547/bct-2020-001>

### ***Guideline***

## **HSCT Guidelines for Transplant Practices During the COVID-19 Pandemic in India [ISBMT DOCUMENT Version1.0]**

SharatDamodar<sup>1</sup>, Vivek S Radhakrishnan<sup>2</sup>, Joseph John M<sup>3</sup>, Pankaj Malhotra<sup>4</sup>, Reetu Jain<sup>5</sup>, Sameer Melinkeri<sup>6</sup>, Jose Easow<sup>7</sup>, Alok Srivastava<sup>8</sup>, on behalf of the Indian Society for Blood and Marrow Transplantation(ISBMT)

<sup>1</sup>Mazumdar Shaw Medical Center, Narayana Health City, Bengaluru, <sup>2</sup>Tata Medical Center, Kolkata, <sup>3</sup>Christian Medical College, Ludhiana, <sup>4</sup>Post Graduate Institute of Medical Education and Research, Chandigarh, <sup>5</sup>Jaslok Hospital & Research Center, Mumbai, <sup>6</sup>Deenanath Mangeshkar Hospital and Research Center, Pune, <sup>7</sup>Apollo Hospital, Chennai, <sup>8</sup>Christian Medical College, Vellore

Blood Cell Therapy Volume 3 (2020) Issue 3 No.4 Pages 59-70

Submitted:May 15, 2020 Accepted:May 26, 2020 Published online:May 28, 2020

DOI:<https://doi.org/10.31547/bct-2020-003>

## *Case Report*

### **Post-HSCT relapsed precursor B-cell ALL successfully salvaged by BiTE followed by consolidation CAR-T cell therapy: A report of two cases**

Wei-Han Huang<sup>1,5,6,7</sup>, Chun-Rong Tong<sup>2</sup>, Tong Wu<sup>3</sup>, Yun-Chu Lin<sup>4</sup>, Chi-Cheng Li<sup>5,6,7</sup>

<sup>1</sup>Department of Clinical Pathology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan,

<sup>2</sup>Department of Hematology, Beijing Boren Hospital, Beijing, China, <sup>3</sup>Department of Bone Marrow Transplantation,

Beijing Boren Hospital, Beijing, China, <sup>4</sup>Department of Hematologic Oncology, National Taiwan University Cancer

Center, Taipei, Taiwan, <sup>5</sup>Department of Hematology & Oncology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical

Foundation, Hualien, Taiwan, <sup>6</sup>Center of Stem Cell and Precision Medicine, Hualien Tzu Chi Hospital, Buddhist Tzu

Chi Medical Foundation, Hualien, Taiwan, <sup>7</sup>School of Medicine, Tzu Chi University, Hualien, Taiwan

Blood Cell Therapy Volume 3 (2020) Issue 4 No.1 Pages 71-73

Submitted: March 29, 2020 Accepted: June 12, 2020 Published online: August 4, 2020

DOI: <https://doi.org/10.31547/bct-2020-002>

## *Case Report*

### **Salvage Transplantation with Cord Blood for Graft Rejection of Peripheral Blood Stem Cells due to Donor Specific Antibody**

Maria Regina Pelobello de Leon<sup>1,2</sup>, Shuichiro Takahashi<sup>1,3</sup>, Masahiro Onozawa<sup>1</sup>, Makoto Ito<sup>4</sup>, Manabu Nakano<sup>5</sup>,

Hajime Senjo<sup>1</sup>, Masahiro Chiba<sup>1</sup>, Hiroyuki Ohigashi<sup>1</sup>, Emi Yokoyama<sup>1</sup>, Junichi Sugita<sup>1</sup>, Daigo Hashimoto<sup>1</sup>, Takanori

Teshima<sup>1</sup>

<sup>1</sup>Department of Hematology, Faculty of Medicine, Hokkaido University, Sapporo, Japan, <sup>2</sup>Department of Medicine,

Section of Hematology, Makati Medical Center, Makati City, Philippines, <sup>3</sup>Sapporo Hokuyū Hospital, Sapporo, Japan,

<sup>4</sup>Division of Laboratory and Transfusion Medicine, Hokkaido University Hospital, Sapporo, Japan, <sup>5</sup>Japanese Red

Cross Hokkaido Block Blood Center, Sapporo, Japan

Blood Cell Therapy Volume 3 (2020) Issue 4 No.2 Pages 74-77

Submitted: May 18, 2020 Accepted: June 26, 2020 Published online: August 31, 2020

DOI: <https://doi.org/10.31547/bct-2020-004>

## *Original Article*

### **A Novel Hematopoietic Progenitor Cell Mobilization Regimen Comprising Bortezomib, G-CSF, and Preemptive Plerixafor for Multiple Myeloma**

Kazuki Tanimoto, Keiji Sakamoto, Ichiro Kawano, Ikumi Yamanaka, Hideho Henzan

Department of Hematology and Oncology, Japanese Red Cross Fukuoka Hospital, Fukuoka, Japan

Blood Cell Therapy Volume 3 (2020) Issue 4 No.3 Pages 78-83

Submitted: May 25, 2020 Accepted: July 29, 2020 Published online: October 9, 2020

DOI: <https://doi.org/10.31547/bct-2020-006>

***Original Article***

**Day 0 bone marrow pathology of allogeneic hematopoietic stem cell transplantation is a novel prognostic factor in myeloid malignancies**

Takahiko Sato<sup>1</sup>, Naomi Kawashima<sup>1</sup>, Masafumi Ito<sup>2</sup>, Yoshiko Atsuta<sup>3</sup>, Yusuke Kagaya<sup>1</sup>, Aika Seto<sup>1</sup>, Takanobu Morishita<sup>1</sup>, Nobuaki Fukushima<sup>1</sup>, Yukiyasu Ozawa<sup>1</sup>, Koichi Miyamura<sup>1</sup>

<sup>1</sup>Department of Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan, <sup>2</sup>Department of Pathology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan, <sup>3</sup>Japanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan

Blood Cell Therapy Volume 3 (2020) Issue 4 No.4 Pages 84-91

Submitted: June 6, 2020 Accepted: August 9, 2020 Published online: October 16, 2020

DOI: <https://doi.org/10.31547/bct-2020-007>

***Original Article***

**Autologous stem cell transplantation (ASCT) outcome for multiple myeloma in a tertiary referral centre in Malaysia**

Christopher Chin Keong Liam<sup>1</sup>, Yang Liang Boo<sup>1</sup>, Yi Lin Lee<sup>2</sup>, Kian Boon Law<sup>2</sup>, Kim Wah Ho<sup>1</sup>, Syed Abdul Kadir Sharifah Shahnaz<sup>1</sup>, Jerome Tsen Chuen Tan<sup>1</sup>, Ngee Siang Lau<sup>1</sup>, Tee Chuan Ong<sup>1</sup>, Sen Mui Tan<sup>1</sup>, Jameela Sathar<sup>1</sup>

<sup>1</sup>Department of Haematology, Ampang Hospital, Selangor, Malaysia, <sup>2</sup>Centre for Clinical Trial, Ampang Hospital, Selangor, Malaysia

Blood Cell Therapy Volume 4 (2021) Issue 1 No.1 Pages 1-8

Submitted: July 1, 2020 Accepted: September 15, 2020 Published online: December 4, 2020

DOI: <https://doi.org/10.31547/bct-2020-009>

***Original Article***

**Dynamics of Epstein-Barr virus after cord blood transplantation: A nationwide survey in Japan**

Akihisa Sawada<sup>1</sup>, Shuichi Taniguchi<sup>2</sup>, Satoshi Takahashi<sup>3</sup>, Masami Inoue<sup>1</sup>, Yasushi Onishi<sup>4</sup>, Masatsugu Tanaka<sup>5</sup>, Hideho Henzan<sup>6</sup>, Masayuki Kubo<sup>7</sup>, Aya Nishida<sup>2</sup>, Keisei Kawa<sup>1</sup>

<sup>1</sup>Department of Hematology/Oncology, Osaka Women's and Children's Hospital, Izumi, Japan, <sup>2</sup>Department of Hematology, Toranomon Hospital, Tokyo, Japan, <sup>3</sup>Division of Molecular Therapy, The Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan, <sup>4</sup>Department of Hematology and Rheumatology, Tohoku University Hospital, Sendai, Japan, <sup>5</sup>Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan, <sup>6</sup>Department of Hematology, Hamanomachi Hospital, Fukuoka, Japan, <sup>7</sup>Department of Respiratory Medicine, Allergology and Hematology, Nara Medical University Hospital, Kashihara, Japan

Blood Cell Therapy Volume 4 (2021) Issue 1 No.2 Pages 9-14

Submitted: July 8, 2020 Accepted: October 3, 2020 Published online: December 11, 2020 Issued

DOI: <https://doi.org/10.31547/bct-2020-010>

## *Case Report*

### **Pharmacokinetics of anti-thymocyte globulin in a patient with severe aplastic anemia treated with allogeneic bone marrow transplantation from a matched unrelated donor**

Noriaki Kawano<sup>1</sup>, Kana Matsumoto<sup>2</sup>, Akiyoshi Takami<sup>3</sup>, Taro Tochigi<sup>1</sup>, Shuro Yoshida<sup>1</sup>, Takuro Kuriyama<sup>1</sup>, Takashi Nakaike<sup>1</sup>, Tomonori Shimokawa<sup>1</sup>, Kiyoshi Yamashita<sup>1</sup>, Koichi Mashiba<sup>1</sup>, Ikuo Kikuchi<sup>1</sup>, Shinji Nakao<sup>4</sup>

<sup>1</sup>Department of Internal Medicine, Miyazaki Prefectural Miyazaki Hospital, Miyazaki, Japan, <sup>2</sup>Department of Clinical Pharmaceutics, Faculty of Pharmaceutical Sciences, Doshisha Women's College of Liberal Arts, Kyotanabe, Japan,

<sup>3</sup>Division of Hematology, Department of Internal Medicine, Aichi Medical University School of Medicine, Yazakokarimata, Nagakute, Japan, <sup>4</sup>Department of Hematology, Faculty of Medicine, Institute of Medical Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan

Blood Cell Therapy Volume 4 (2021) Issue 1 No.3 Pages 15-19

Submitted: August 4, 2020 Accepted: October 26, 2020 Published online: December 28, 2020

DOI: <https://doi.org/10.31547/bct-2020-012>

## *Original Article*

### **The 2016 APBMT Activity Survey Report: Trends in haploidentical and cord blood transplantation in the Asia-Pacific region**

Minako Iida<sup>1</sup>, Anthony Dodds<sup>2</sup>, Mafruha Akter<sup>3</sup>, Alok Srivastava<sup>4</sup>, Joon Ho Moon<sup>5</sup>, Phu Chi Dung<sup>6</sup>, Marjorie Rose Bravo<sup>7</sup>, Aya Aya Gyil<sup>8</sup>, Devinda Jayathilake<sup>9</sup>, Kaiyan Liu<sup>10</sup>, Bor-Sheng Ko<sup>11</sup>, Amir Hamidieh<sup>12</sup>, Kim Wah Ho<sup>13</sup>, Aloysius Ho<sup>14</sup>, Artit Ungkanont<sup>15</sup>, Tasneem Farzana<sup>16</sup>, Joycelyn Sim<sup>17</sup>, Bishesh Poudyal<sup>18</sup>, Khishigjargal Batshkh<sup>19</sup>, Shinichiro Okamoto<sup>20</sup>, Yoshiko Atsuta<sup>21</sup>, Registry Committee of the Asia-Pacific Blood and Marrow Transplantation Group (APBMT)

<sup>1</sup>Department of Promotion for Blood and Marrow Transplantation, Aichi Medical University School of Medicine, Nagakute, Japan, <sup>2</sup>St. Vincent's Pathology, St. Vincent's Health Network, Sydney, and Australasian Bone Marrow Transplant Recipient Registry (ABMTRR), Sydney, Australia, <sup>3</sup>Department of Hematology and BMT, Dhaka Medical College and Hospital, Dhaka, Bangladesh, <sup>4</sup>Department of Haematology, Christian Medical College Hospital, Vellore, India, <sup>5</sup>Division of Hematology-Oncology, Department of Internal Medicine, Kyungpook National University Hospital, Daegu, Republic of Korea, <sup>6</sup>Stem Cell Transplantation Department, Blood Transfusion and Hematology Hospital, Ho Chi Minh, Vietnam, <sup>7</sup>St Luke's Medical Center Quezon City, IM Hematology/Blood and Marrow Transplant, Quezon, Philippines, <sup>8</sup>Department of Clinical Haematology, North Okkalapa General Hospital, Yangon, Myanmar, <sup>9</sup>Department of Oncology, National Cancer Institute, Maharagama, Sri Lanka, <sup>10</sup>Department of Hematology, Peking University Institute of Hematology, Beijing, China, <sup>11</sup>Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan, <sup>12</sup>Pediatric Cell Therapy Research Center, Tehran University of Medical Sciences, Tehran, Iran, <sup>13</sup>Department of Hematology, Hospital Ampang, Ampang Selangor, Malaysia, <sup>14</sup>Department of Haematology, Singapore General Hospital, Singapore, <sup>15</sup>Chakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Samut Prakan, Thailand, <sup>16</sup>Department of Clinical Haematology, National Institute of Blood Disease and Bone Marrow Transplantation, Karachi, Pakistan, <sup>17</sup>Department of Medicine, Queen Mary Hospital, Hong Kong, <sup>18</sup>Civil Service Hospital, Clinical Hematology and Bone Marrow Transplant Unit, Kathmandu, Nepal,

<sup>19</sup>Bone and Marrow transplantation team, Hematology Department, National First Central Hospital of Mongolia, Ulaanbaatar, Mongolia, <sup>20</sup>Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan, <sup>21</sup>Japanese Data Center for Hematopoietic Cell Transplantation(JDCHCT), Nagoya, Japan  
Blood Cell Therapy Volume 4 (2021) Issue 2 No.1 Pages 20-28  
Submitted:September 3, 2020 Accepted:November 13, 2020 Published online:January 29, 2021  
DOI:<https://doi.org/10.31547/bct-2020-013>

### *Original Article*

## **T-cell replete Haplo-identical HSCT with Post transplant Cyclophosphamide for Hemoglobinopathies: A retrospective analysis from a single center**

Dharma Choudhary, Divya Doval, Sanjeev Kumar Sharma, Vipin Khandelwal, Rasika Setia, Anil Handoo

Centre for Bone Marrow Transplant, BLK Superspeciality Hospital, Pusa Road, New Delhi, India

Blood Cell Therapy Volume 4 (2021) Issue 2 No.2 Pages 29-34

Submitted:September 24, 2020 Accepted:November 14, 2020 Published online:January 15, 2021

DOI:<https://doi.org/10.31547/bct-2020-014>

### *Review Article*

## **Hematopoietic cell transplantation in adults with acute myeloid leukemia: A review of the results from various nationwide registry studies in Japan**

Yasuyuki Arai<sup>1</sup>, Takaaki Konuma<sup>2</sup>, Masamitsu Yanada<sup>3</sup>

<sup>1</sup>Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan,

<sup>2</sup>Division of Molecular Therapy, The Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan,

<sup>3</sup>Department of Hematology and Cell Therapy, Aichi Cancer Center, Nagoya, Japan

Blood Cell Therapy Volume 4 (2021) Issue 2 No.3 Pages 35-43

Submitted:December 22, 2020 Accepted:February 10, 2021 Published online:April 2, 2021

DOI:<https://doi.org/10.31547/bct-2020-023>

### *Case Report*

## **Successful treatment with lenalidomide for relapsed adult T-cell leukemia/lymphoma after cord blood cell transplantation**

Katsumichi Fujimaki<sup>1</sup>, Yuto Hibino<sup>1</sup>, Kumiko Kishimoto<sup>1</sup>, Shinichiro Watanabe<sup>2</sup>, Satoshi Koyama<sup>3</sup>, Taiki Ando<sup>3</sup>, Heiwa Kanamori<sup>3</sup>, Hideaki Nakajima<sup>4</sup>

<sup>1</sup>Department of Hematology, Fujisawa City Hospital, Kanagawa, Japan, <sup>2</sup>Department of Clinical Laboratory Medicine, Fujisawa City Hospital, Kanagawa, Japan, <sup>3</sup>Department of Hematology, Kanagawa Cancer Center, Kanagawa, Japan,

<sup>4</sup>Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Kanagawa, Japan

Blood Cell Therapy Volume 4 (2021) Issue 2 No.4 Pages 44-47

Submitted:November 25, 2020 Accepted:March 2, 2021 Published online:April 30, 2021 Issued

DOI:<https://doi.org/10.31547/bct-2020-018>

### ***Original Article***

## **Early bone loss in Indian patients undergoing allogeneic hematopoietic cell transplantation**

Niranjan S. Khaire<sup>1</sup>, Arjun Dinesani<sup>1</sup>, Anindita Sinha<sup>2</sup>, Sanjay Bhadada<sup>3</sup>, Pankaj Malhotra<sup>1</sup>, Alka Khadwal<sup>1</sup>, Gaurav Prakash<sup>1</sup>, Arihant Jain<sup>1</sup>, Aditya Jandial<sup>1</sup>, Deepesh P. Lad<sup>1</sup>

<sup>1</sup>Department of Internal Medicine, <sup>2</sup>Radiodiagnosis, <sup>3</sup>Endocrinology, Postgraduate Institute of Medical Education and Research

Blood Cell Therapy Volume 4 (2021) Issue 3 No.1 Pages 48-53

Submitted:December 1, 2020 Accepted:March 16, 2021 Published online:August 25, 2021

DOI:<https://doi.org/10.31547/bct-2020-019>

### ***Original Article***

## **Efficacy and safety of venetoclax in combination therapy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation**

Fan Yang, Yueqian Feng, Changwei Dong, Zhihui Li, Tong Wu

Department of Bone Marrow Transplantation, Beijing Boren Hospital, Beijing, China

Blood Cell Therapy Volume 4 (2021) Issue 3 No.2 Pages 54-57

Submitted:December 31, 2020 Accepted:March 20, 2021 Published online:August 25, 2021

DOI:<https://doi.org/10.31547/bct-2020-025>

### ***Original Article***

## **Higher Starting Dose of Ciclosporin Optimized Therapeutic Levels in Patients Receiving Phenytoin for Busulfan-induced Seizure Prophylaxis**

Ying Shi Ho<sup>1</sup>, Mui Fong Chong<sup>1</sup>, Vin Cci Ng<sup>1</sup>, Aloysius Ho<sup>2</sup>, Hong Yen Ng<sup>1</sup>

<sup>1</sup>Department of Pharmacy, Singapore General Hospital, Singapore, <sup>2</sup>Department of Hematology, Singapore General Hospital, Singapore

Blood Cell Therapy Volume 4 (2021) Issue 3 No.3 Pages 58-64

Submitted:December 20, 2020 Accepted:April 1, 2021 Published online:August 25, 2021 Issued

DOI:<https://doi.org/10.31547/bct-2020-022>

### ***Original Article***

## **Late Effects of Allogeneic Hematopoietic Stem Cell Transplantation in an Asian Patient Population**

Chong Mui Fong, Lim Yan Jiun, Ng Hong Yen

Department of Pharmacy, Singapore General Hospital, Singapore

Blood Cell Therapy Volume 4 (2021) Issue 3 No.4 Pages 65-74

Submitted:December 19, 2020 Accepted:May 5, 2021 Published online:August 25, 2021 Issued

DOI:<https://doi.org/10.31547/bct-2020-020>

### ***State of the Art***

## **Toxicity of Chimeric Antigen Receptor T Cells and its Management**

Kitsada Wudhikarn<sup>1</sup>, Shui Yen Soh<sup>2</sup>, He Huang<sup>3</sup>, Miguel-Angel Perales<sup>4,5</sup>

<sup>1</sup>Division of Hematology and Research Unit in Translational Hematology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand, <sup>2</sup>Paediatric Haematology/Oncology Service, KK Women's and Children's Hospital, Singapore, <sup>3</sup>The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China, <sup>4</sup>Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA, <sup>5</sup>Department of Medicine, Weill Cornell Medical College, New York, NY, USA

Blood Cell Therapy Volume 4 (2021) Special Edition No.1 Pages S1-S7

Submitted:August 7, 2021 Accepted:August 15, 2021 Published online:October 14, 2021 Issued

DOI:<https://doi.org/10.31547/bct-2021-011>

### ***State of the Art***

## **Highlights of Pharmacist Roles in Hematopoietic Cell Transplantation and Cellular Therapy**

Ho Ying Shi<sup>1</sup>, Trai Tharnpanich<sup>2</sup>, Bo Yu<sup>3</sup>

<sup>1</sup>Department of Pharmacy, Singapore General Hospital, Singapore, <sup>2</sup>Faculty of Pharmaceutical Sciences Chulalongkorn University, Bangkok, Thailand, <sup>3</sup>Department of Pharmacy, and Clinical Research Institute Office, Tongren Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, China

Blood Cell Therapy Volume 4 (2021) Special Edition No.2 Pages S8-S13

Submitted:August 20, 2021 Accepted:August 20, 2021 Published online:October 14, 2021

DOI:<https://doi.org/10.31547/bct-2021-016>

### ***State of the Art***

## **Standardization and Accreditation in Haemopoietic Stem Cell Transplantation – an Asia Pacific Perspective**

Sharat Damodar<sup>1</sup>, David D Ma<sup>2,3</sup>, Scott J Ragg<sup>4</sup>, Annabella Chang<sup>5</sup>, William YK Hwang<sup>6</sup>, Aloysius YL Ho<sup>6</sup>, Alok Srivastava<sup>7</sup>

<sup>1</sup>Dept of Haematology and BMT, Mazumdar shaw medical center, Narayana health city, India, <sup>2</sup>Department of Haematology and BM Transplant, St Vincent's Hospital Sydney, NSW, Australia, <sup>3</sup>St Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, NSW, Australia, <sup>4</sup>Royal Hobart Hospital, Hobart. TAS. Australia, <sup>5</sup>St Vincent's Centre for Applied Medical Research, Sydney NSW Australia, <sup>6</sup>Department of Haematology, Singapore General Hospital, Singapore, <sup>7</sup>Dept of Haematology, CMC Vellore, India

Blood Cell Therapy Volume 4 (2021) Special Edition No.3 Pages S14-S19

Submitted:August 17, 2021 Accepted:August 25, 2021 Published online:October 14, 2021  
DOI:<https://doi.org/10.31547/bct-2021-015>

### ***State of the Art***

## **Allogeneic Hematopoietic Cell Transplantation and Cellular Therapy**

Hee-Je Kim<sup>1</sup>, Daniel Weisdorf<sup>2</sup>, David J Gottlieb<sup>3</sup>

<sup>1</sup>Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, the Republic of Korea, <sup>2</sup>Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, U.S.A, <sup>3</sup>Westmead Hospital University of Sydney, Sydney, Australia

Blood Cell Therapy Volume 4 (2021) Special Edition No.4 Pages S20-S27

Submitted:August 16, 2021 Accepted:September 1, 2021 Published online:October 14, 2021  
DOI:<https://doi.org/10.31547/bct-2021-014>

### ***Original Article***

## **Haploidentical Hematopoietic Stem Cell Transplant Using Post-transplant Cyclophosphamide: A Single-Center Initial Experience in Vietnam**

Man Van Huynh, Quang The Nguyen, Phu Duc Vinh Huynh, Nam Duy Hoang, Thu Hanh Nguyen, Dung Chi Phu  
Stem Cell Transplantation Department, Blood Transfusion Hematology Hospital, Ho Chi Minh City, Vietnam

Blood Cell Therapy Volume 4 (2021) Issue 4 No.1 Pages 75-83

Submitted:April 1, 2021 Accepted:May 30, 2021 Published online:November 25, 2021 Issued  
DOI:<https://doi.org/10.31547/bct-2021-002>

### ***Short Communication***

## **Impact of COVID-19 on peripheral stem cell collection and preservation at a hematopoietic cell transplant center in India: Experience 2020**

Rizwan Javed<sup>1</sup>, Mita Roychowdhury<sup>2</sup>, Saurabh Bhave<sup>3</sup>, Arijit Nag<sup>3</sup>, Jeevan Kumar<sup>3</sup>, Vivek Radhakrishnan<sup>3</sup>, Sanjay Bhattacharya<sup>4</sup>, Deepak Kumar Mishra<sup>5</sup>, Niharendu Ghara<sup>6</sup>, Reghu RS<sup>6</sup>, Reena Nair<sup>3</sup>, Mammen Chandy<sup>3</sup>

<sup>1</sup>Apheresis & Cell processing unit, Department of Clinical Haematology and BMT, TATA Medical Center, Kolkata, <sup>2</sup>TATA Medical Center, Kolkata, <sup>3</sup>Department of Clinical Haematology and BMT, TATA Medical Center, Kolkata, <sup>4</sup>Microbiology, TATA Medical Center, Kolkata, <sup>5</sup>Laboratory Haematology, TATA Medical Center, Kolkata, <sup>6</sup>Department of Paediatric Haemato-Oncology, TATA Medical Center, Kolkata

Blood Cell Therapy Volume 4 (2021) Issue 4 No.2 Pages 84-87

Submitted:May 27, 2021 Accepted:July 16, 2021 Published online:November 25, 2021 Issued  
DOI:<https://doi.org/10.31547/bct-2021-004>

### ***Case Report***

## **Severe graft-versus-host disease of the lower intestinal tract after pomalidomide administration in a plasma cell leukemia patient following bone marrow transplantation**

Hiroto Ishii, Hiroki Yokoyama, Atsushi Katsube, Tadahiro Gunji, Takeshi Saito, Shingo Yano

Division of Clinical Oncology and Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan

Blood Cell Therapy Volume 4 (2021) Issue 4 No.3 Pages 88-91

Submitted: June 6, 2021 Accepted: August 3, 2021 Published online: November 25, 2021 Issued

DOI: <https://doi.org/10.31547/bct-2021-006>

### ***Original Article***

## **HEMATOPOIETIC STEM CELL TRANSPLANT IN AGGRESSIVE T AND NK/T CELL LYMPHOMA – ROLE OF UPFRONT AUTOLOGOUS TRANSPLANT IN NODAL PERIPHERAL T-CELL LYMPHOMA**

Lawrence Cheng Kiat Ng<sup>1</sup>, Christopher Shwei Wen Tham<sup>1</sup>, Francesca Wei Inng Lim<sup>1</sup>, Yunxin Chen<sup>1</sup>, Shin Yeu Ong<sup>1</sup>, Chandramouli Nagarajan<sup>1</sup>, Jing Jing Lee<sup>1</sup>, Yeow Tee Goh<sup>1</sup>, Yeh Ching Linn<sup>1</sup>, Yuh Shan Lee<sup>1,2</sup>, Colin Diong Phipps<sup>1,2</sup>, Jeffrey Kim Siang Quek<sup>1</sup>, Than Hein<sup>1</sup>, Jordan Chung Cheng Hwang<sup>1</sup>, Nicholas Grigoropoulos<sup>1</sup>, William Ying Khee Hwang<sup>1</sup>, Aloysius Yew Leng Ho<sup>1</sup>

<sup>1</sup>Department of Haematology, Singapore General Hospital, Singapore, <sup>2</sup>Parkway Cancer Centre, Singapore

Blood Cell Therapy Volume 4 (2021) Issue 4 No.4 Pages 92-100

Submitted: June 8, 2021 Accepted: August 7, 2021 Published online: November 25, 2021 Issued

DOI: <https://doi.org/10.31547/bct-2021-007>

### ***State of the Art***

## **Novel Treatment for Graft-versus-Host Disease**

Yoshihiro Inamoto<sup>1</sup>, Robert Zeiser<sup>2</sup>, Godfrey Chi-Fung Chan<sup>3,4,5</sup>

<sup>1</sup>Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan, <sup>2</sup>Department of Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, Albert Ludwigs University (ALU), Freiburg, Germany, <sup>3</sup>Department of Paediatrics and Adolescent Medicine, LKS Faculty of Medicine, The University of Hong Kong, <sup>4</sup>Department of Paediatrics and Adolescent Medicine, Hong Kong Children's Hospital, <sup>5</sup>Department of Paediatrics and Adolescent Medicine, HKU-Shenzhen Hospital

Blood Cell Therapy Volume 4 (2021) Issue 4 No.5 Pages 101-109

Submitted: October 1, 2021 Accepted: October 16, 2021 Published online: November 25, 2021

DOI: <https://doi.org/10.31547/bct-2021-022>

# Appendix

## Cooperate Members

<b>Annual sponsorship</b>	Center for Supporting Hematology-Oncology Trials
	Astellas
	AIR WATER
<b>Banner Contributions</b>	MSD
<b>International sponsorship for the APBMT 2021 Thailand</b>	Kite Pharma
	Terumo Thailand
	Miltenyi

# APBMT Annual Report 2021

## APBMT officers

### President



Shinichiro Okamoto  
Department of Medicine  
Keio University School of Medicine  
35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan  
Tel: +81 3 3335 1221  
okamoto.a7@keio.jp

### Secretariat office

**E-mail: [office@apbmt.org](mailto:office@apbmt.org)**

**Website: <http://www.apbmt.org>**

Department of Promotion for Blood and Marrow  
Transplantation

Aichi Medical University School of Medicine

1-1 Yazakokarimata, Nagakute, Aichi, 480-1195, Japan

Tel: +81 561 62 3311 (Ext. 12375) Fax: +81 561 61 3180



Minako Iida  
[miida@aichi-med-u.ac.jp](mailto:miida@aichi-med-u.ac.jp)



Yukari Nakao  
[yukari-nakao@aichi-med-u.ac.jp](mailto:yukari-nakao@aichi-med-u.ac.jp)



Hiroe Namizaki  
[namizaki@aichi-med-u.ac.jp](mailto:namizaki@aichi-med-u.ac.jp)

**Asia-Pacific Blood and Marrow Transplantation Group**  
**SECRETARIAT OFFICE / DATA CENTER OF APBMT**